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ABSTRACT 
 
Background and Objectives: The reporting of adverse drug reactions (ADRs) is 
a major public health necessity. It is estimated that only six to 10 percent of all 
ADRs are reported worldwide. This number is far less than the actual cases of 
ADRs which occur in healthcare facilities. There appears to be lack of knowledge, 
awareness and willingness of healthcare professionals to report ADRs, which 
prompted some countries to nominate a person for ADR reporting in facilities. The 
objectives of this study were to ascertain which facilities had a nominated person 
or committee for ADR reporting, describe the knowledge and training of these 
individuals, describe the processes followed by the facilities for ADR reporting, 
determine the most commonly reported ADRs and causative drug classes, and, 
determine the factors which facilitate or hinder ADR reporting. 
Method: This was an exploratory, multicenter study. A structured questionnaire 
with closed and open-ended questions was used for data collection. The study 
was conducted in Gauteng province, where stratified non-random sampling was 
used to collect data in the selected regional and district public hospitals. 
Results: Six regional hospitals and five district hospitals participated in the study. 
Five (45.5%) of these hospitals had a person nominated for ADR reporting, of 
which all were pharmacists. All the respondents nominated for ADR reporting 
stated their knowledge and confidence in identification of ADRs as average and 
above. One (20%) of the nominated persons for ADR reporting did not have 
pharmacovigilance training. The reported number of ADRs over the past 12 
months ranged between zero and 199. Only two (40%) of the hospitals with a 
nominated person for ADR reporting received feedback on the submitted reports 
from a committee.  
Only one (16.7%) of the six hospitals that did not have a nominated person or 
committee for ADR reporting had plans to nominate a person for this function. 
ADR reporting in these hospitals were performed by the pharmacy that collated 
the identified ADRs into a report and distributed these to the Pharmacy and 
Therapeutics Committee (PTC) and South African Health Products Regulatory 
Authority (SAHPRA). 
Only one hospital out of all the hospitals (n=11) did not use the national ADR 
reporting form and rather used an incident report. Out of all the participating 
hospitals, only two (18.2%) of the hospitals had an algorithm in place to assist with 
the identification of ADRs. The researcher went through the file where ADR 
reporting forms were kept for the past 12 months, and reported that the most 
commonly reported ADR type across participating facilities was allergic reactions 
such as rash and angioedema reported by eight of the facilities, followed by 
administration errors and quality issues each from three facilities. While the most 
frequently reported drug class associated with these ADRs included antiretrovirals 
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(ARVs) and angiotensin converting enzyme (ACE) inhibitors reported at eight and 
six facilities, respectively.  
The most common challenge to ADR reporting at participating facilities was non-
reporting of ADRs, followed by fear of litigation and patient’s unwillingness. 
Although all the hospitals in this study had facility PTCs, only one hospital had a 
pharmacovigilance subcommittee and the others included ADRs as an agenda 
point of the PTC meetings. 
Conclusion: Less than half of the facilities had a person nominated for ADR 
reporting. Pharmacists and the pharmacy were synonymous with ADR reporting 
as all nominated persons were pharmacists and in facilities were there were no 
nominated person, the responsible pharmacist was identified as the contact 
person for ADR reporting. Although all hospitals had PTCs, there was rarely a 
subcommittee dedicated to pharmacovigilance or ADR reporting, which culminated 
in a lack of feedback to healthcare workers that could promote it in the facility. 
Underreporting of ADRs by health care workers was the major challenge to 
effective ADR reporting as this function was considered to be too time consuming. 
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1. CHAPTER 1: INTRODUCTION 
 
Pharmacovigilance has been defined by the World Health Organization (WHO) as: 
“The science and activities relating to the detection, assessment, understanding 
and prevention of adverse effects or any other possible drug-related problems” 
(WHO, 2006). An adverse drug reaction (ADR) is defined by the WHO as a drug 
response, that is noxious, unintended and occurs at normal doses of medicine 
used in man (WHO, 2002). The reporting of ADRs is a major public health 
necessity. This means that it requires organised efforts of the society to protect, 
promote and restore patient’s health as it may have a significant impact on 
mortality and morbidity caused by drugs (WHO, 2006; Mouton et al., 2015). 
ADR reporting is especially of value for newly registered drugs, because safety 
information gathered during the early phases of drug development, has significant 
limitations on the rare but serious adverse reactions, chronic toxicity, use in 
special groups or interaction with other drugs. This warrants the need for phase 4 
of drug development namely, post-marketing surveillance (WHO, 2002). Post-
marketing surveillance may be defined as the continuous monitoring of drugs after 
they reach the market in real clinical settings, taken by a variety of patients with 
various co-morbidities, over a prolonged period to detect previously unrecognized 
drug related effects, positive or negative (Vlahovic-Palcevski and Mentzer, 2011). 
In the United States, there has been much focus on pharmacovigilance strategies 
especially with a trend towards expedited drug registrations (Carroll, 2005). 
Accordingly, in 1993, the European law introduced the requirement for a qualified 
person nominated for pharmacovigilance in each pharmaceutical company 
(Brown, 2005).  
However, the effectiveness of post-marketing surveillance is directly dependent on 
ADR reporting by healthcare professionals and patients in clinical practice (Palleria 
et al., 2013). Historically, spontaneous reporting of ADRs played a vital role in the 
detection, evaluation, understanding and prevention of unsuspected, serious and 
unusual ADRs (Wysowsky and Swartz, 2005). Spontaneous reporting, also known 
as voluntary reporting is the passive surveillance of product safety where ADRs 
are reported by healthcare workers and patients, subsequent to administration of a 
medicinal product (Al Dweik, et al., 2016). Successful spontaneous reporting of 
ADRs has been linked to a health care worker’s knowledge of the importance of 
pharmacovigilance, coupled with the skills necessary to identify and report ADRs 
(Ruud et al., 2010). In addition, all clinical settings have a team of health care 
workers and ADRs can be identified by any member of this team. The coordination 
between team members regarding who will report the identified ADR is a crucial 
link for an effective pharmacovigilance effort. 
https://etd.uwc.ac.za
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ADRs vary in their classification from minor to serious. Patients presenting with 
serious ADRs usually end up in hospital, which illustrate the need for an active, 
more responsive pharmacovigilance system for hospital settings. Indeed, several 
studies conducted in a variety of international settings indicated a range between 
two and 21% of patients were being admitted to hospital with ADRs (Lobo et al., 
2013; Brandao and Vasconcelos, 2000; Einarson, 1993). The WHO introduced 
Pharmacy and Therapeutics Committees (PTCs) in hospitals to serve several 
functions which include, but not limited to the selection of efficacious and cost-
effective medicine, efficient procurement practices, reduction of medicine wastage, 
ensuring efficient prescribing practices in accordance with standard treatment 
guidelines/protocols and dispensing practices (WHO, 2003). In addition, PTCs are 
encouraged to establish subcommittees to support them in their functions and one 
of the essential subcommittee’s is the pharmacovigilance or safety and quality 
committee, which includes ADR monitoring (Strengthening Pharmaceutical 
Systems, 2012). 
In 2006, countries such as Italy issued a Legislative Decree that all hospitals 
should have a nominated person for ADR reporting, where healthcare 
professionals are bound by duty to report all suspected ADRs using an appropriate 
form and send it to the nominated pharmacovigilance person, who verifies the 
completeness, accuracy and consistency of the reported information (Mazzitello et 
al., 2013).In general, the nomination of a responsible person for ADR reporting is 
an important step towards building robust pharmacovigilance systems in the 
clinical setting (Khan et al., 2013). In cases where such a person does not exist, it 
has been recommended that PTCs be approached to nominate such a person 
(Jobson, 2003). 
In addition to single facility reporting, pharmacoviliance activities need to be 
collated at higher levels in order for it to give an overall picture of a drug. Efforts 
have thus been made for all countries to collaborate at an international level for 
drug monitoring. In the year 2002, more than 65 countries came together and 
formed the Uppsalla Monitoring Centre (UMC), which is coordinated by the WHO 
Collaborating Centre for International Drug Monitoring (Jeetu and Anusha, 2010).  
The main function of this centre is to manage the international ADR reports 
database received from national centres (Olsson,1998). National 
Pharmacovigilance Centres have a crucial role in increasing public awareness on 
drug safety. Countries such as New Zealand, Sweden, United States of America 
and the United Kingdom have strategically placed national and regional 
pharmacovigilance centres in medical schools, hospitals or poison and drug 
information centres rather than housing them within the confines of a drug 
regulatory authority (Jeetu and Anusha, 2010). 
https://etd.uwc.ac.za
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1.1 Problem Statement 
It is estimated that only six to ten percent of all hospital ADRs are reported globally 
(Wysowsky and Swartz, 2005). Indeed, the number of reported ADRs is far less 
than the actual number of cases which occur in health facilities (Wysowsky and 
Swartz, 2005; Khan et al, 2013). Underreporting of ADRs is a global issue and in 
South Africa, there appears to be lack of knowledge, awareness and willingness of 
healthcare professionals for ADR reporting (Ampadu et al., 2016; Bogolubova et 
al., 2018). In South Africa, the Medicines Control Council (MCC), now known as 
the South African Health Products Regulatory Authority (SAHPRA) has a unit 
called the National Adverse Drug Events Monitoring Centre (NADEMC) which was 
established to manage the ADR database, however, the reporting rates are still 
low (Terblance, 2018; Bongolubova et al., 2018). 
Developing and underdeveloped countries such as South Africa obtain 
pharmacovigilance information of new drugs from developed countries which have 
effective pharmacovigilance systems already in place. However this may not be 
appropriate as factors such as cultural, genetics, geographical and other local 
factors need to be taken into consideration (Toklu et al., 2016). Traditionally, 
pharmacovigilance activities were limited to spontaneous reporting of ADRs, which 
has been the mainstay of regulatory pharmacovigilance activities for many years 
(Mehta, 2011; Mehta et al., 2014). 
Key informants actively involved in pharmacovigilance in India, Uganda and South 
Africa have reported that lack of human resources was the biggest challenge to 
ADR reporting (Maigetter et al., 2015). In addition, much of the data that had been 
collected and sent to the National Adverse Drug Events Monitoring Centres 
(NADEMCs) where not made use of due to insufficient capacity for analysis 
(Maigetter et al., 2015). There was a work backlog of approximately three years 
due to bureaucratic delays at these centres. Pharmacovigilance, in general, was 
perceived mainly as an administrative task since the pharmacists working at the 
national pharmacovigilance program did not have enough administrative staff, 
which meant that they were spending more time doing administrative tasks such 
as capturing data, following-up on incomplete forms and catching-up on a backlog 
of three years, than analysing and interpreting the collected data (Maigetter et al., 
2015). Lack of man power was a challenge with only one chief pharmacist 
employed full-time at NADEMC, while the experts were remunerated on an hourly 
basis (Maigetter et al., 2015). Other concerns that the NADEMCs had to deal with 
included; uncoordinated report submission due to fragmentation between non-
governmental organisations not coordinating with the national system resulting in 
duplicate reports, under-reporting for anti-tuberculosis and anti-retroviral drugs, 
and, inconsistent use of the standard ADR reporting as other non-standard forms 
were also accepted, which resulted in omission of patient details required and an 
inability to track a report. In South Africa, there were also poor communication 
between the NADEMC and healthcare workers doing the reporting as doctors 
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complained that they did not receive feedback concerning the reported ADRs 
while the Medicines Control Council (MCC) responded that there were too many 
reports on which to provide feedback (Maigetter et al., 2015; Alsaleh et al., 2017; 
Valliano et al., 2005). 
One of the primary problems in the South African health care system is that it is 
fragmented into the public and the private health services. The public healthcare 
system is funded by the government and serves more than 70% of the South 
African population for free (GDoH, 2016). Most of these patients are low to 
medium income earners, and cannot otherwise afford private healthcare (Harris et 
al., 2011). As such, public health care is burdened with a high number of patients 
and limited resources, including health care workers. This results in the 
prioritisation of direct patient care activities with the limited time and the 
deprioritisation or neglect of administrative tasks, of which ADR reporting is 
perceived as one. 
Additionally, it is not considered mandatory to report ADRs as there are no policies 
in place which clearly state the responsibility of who should report ADRs (NDoH, 
1996). This responsibility could have been addressed in the National Drug Policy 
(NDP) health objectives, but this policy was focused on the adequate and reliable 
supply of safe, cost-effective medicine of acceptable quality and rational use by all. 
The roles of pharmacists, pharmacy support staff, doctors and nurses are outlined 
in this policy but there is no direct inference to their role in ADR reporting (NDoH, 
1996). Despite the lack of responsibility for ADR reporting, it has also been found 
that ignorance, insecurity, legal diffidence and complacency contribute to poor 
ADR reporting practices (Toklu et al., 2016; Maigetter et al., 2015). 
There is a high number of patients served by the public sector, with long queues, 
shortage of staff, demanding working hours which often overburden healthcare 
workers, and ultimately impacts negatively on the quality of care and patient 
counselling (Visser et al., 2018). This leads to inappropriate use of medicine which 
might be related to the origin of an ADR and/or failure by patients to recognize 
ADRs and report them to health care workers. In addition ADR reporting requires a 
multidisciplinary approach that involves collaboration amongst healthcare workers, 
which is problematic in most settings (Toklu et al., 2016; Khan et al., 2013).There 
seems to be an absence of literature on the availability of persons nominated for 
pharmacovigilance in any of the hospitals in South Africa. 
In South Africa, an observational study was conducted in a secondary teaching 
hospital in Somerset West, Cape Town where hospital admissions due to ADRs 
were found to be 6.3%. In addition, 41% developed while the patients were in 
hospital (Mehta et al., 2008). The same study reported that 46% of these ADRs 
that developed while the patients were admitted in the hospital were preventable. 
These alarming results prompted the researchers to conduct another study to 
evaluate healthcare workers’ knowledge on ADR reporting, where 50% of the 
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respondents expressed that ADR reporting was time consuming, 38.24% did not 
know how to report, 35.29% did not know where to report to, 27.45% said that the 
ADR form was not user friendly, while 17.65% indicated that there was no financial 
incentive (Joubert and Naidoo, 2016). South Africa’s national pharmacovigilance 
and ADR reporting systems are not yet functioning optimally. 
1.2 Rationale for the study 
South Africa became a member of the WHO International Drug Monitoring 
Programme in 1992, which made South Africa the first country in Africa to become 
a member (Maigetter et al., 2015). The National Drug Policy (NDP) has advocated 
for the establishment of PTCs which will ensure efficient, rational and cost-
effective supply and use of medicine (NDoH, 1996; Strengthening Pharmaceutical 
Systems (SPS), 2012). One of the important responsibilities of the PTCs is to 
manage ADRs and rectify medication errors, or nominate a subcommittee or a 
dedicated person for this function (Vang et al., 2006). However, there is no clear 
policy on this function and this has resulted in differences in the objectives and 
functioning of PTCs across facilities in South Africa (Systems for Improved Access 
to Pharmaceuticals and Services (SIAPS), 2014). 
The South African MCC, now referred to as SAHPRA, released a guideline for the 
purpose of ADR reporting by pharmaceutical companies (MCC, 2016), which 
require holders of certificates for the registration of medicines (pharmaceutical 
companies) to nominate a qualified person for pharmacovigilance. However, in 
order for this person to perform their duties, they require end-users of the 
pharmaceutical product to report all suspected and confirmed ADRs (MCC, 2016). 
ADR reporting is thus dependent on the actions of patients and healthcare 
professionals in practice. This limits the ability of pharmaceutical companies to 
comply with these guidelines.  
In the year 2010, The South African National Department of Health compiled the 
revised National Core Standards for health establishments in the country to set the 
standards for quality service, avoid risk to poor quality care and reduce their 
impact. According to these National Core Standards domains, healthcare 
establishments should ensure quality nursing and clinical care and ethical practice, 
reduce unintended harm, prevent or manage problems or adverse events which 
should be routinely analysed and managed to prevent recurrence. However, the 
implementation of the national core standards has not been officially linked to 
performance measurement (NDoH, 2011). 
 
https://etd.uwc.ac.za
Chapter 1: Introduction 
 
6 
 
1.3 Purpose of the study 
1.3.1 Research Question 
What is the status of ADR reporting structures, in terms of human and other 
resources, in public sector hospitals and what are the factors that help or hinder 
the effectiveness of ADR reporting within the existing structure? 
1.3.2 Aim of the study 
The aim of this study was to explore the factors affecting ADR reporting at regional 
and district public sector hospitals in the Gauteng province. 
1.3.3 Objectives of the study 
The objectives of the study were to: 
• Ascertain which facilities had(a) nominated person(s) responsible for ADR 
reporting, 
• Describe the knowledge and training of person(s) nominated for ADR 
reporting, 
• Describe the structure of and processes followed for ADR reporting at each 
facility that did not have a nominated person, 
• Obtain statistics and/or trends of ADR reported by all facilities,  
• Determine the factors that facilitate or hinder ADR reporting for the facility, 
and, 
• To provide recommendations to address challenges associated with ADR 
reporting at hospital level 
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2. CHAPTER 2: LITERATURE REVIEW 
 
This chapter will start with a review of national and facility-based 
pharmacovigilance structures as recommended by WHO, how pharmacovigilance 
fit into patient care at a health facility, and, adverse drug reaction classifications. 
This chapter concludes with the description of factors that affect ADR reporting in 
health facilities. 
2.1 Pharmacovigilance structures 
 
Pharmacovigilance (PV) is a relatively new science and public health activity in 
most underdeveloped and developing countries, when compared to developed 
countries (Ampadu et al., 2016). In South Africa, this function is primarily driven by 
three main stakeholders: regulators and the pharmaceutical industry who are 
focused chiefly on healthcare products; public health programmes, responsible for 
the systems; and healthcare providers, who are focused on patients. All these 
stakeholders have a goal of minimising drug-related harm to the patient (Mehta et 
al., 2017). The WHO together with its regional offices play an important role in 
supporting countries in promoting the establishment and building of sustainable 
monitoring systems for pharmacovigilance (Maigetter et al., 2015). 
The global pharmacovigilance basis is reliant on spontaneous reporting systems, 
which involves the systematic collection of reports, collation, analysis and 
evaluation of the data which enables the detection of signals, their communication 
and risk management (WHO, 2015). At a local level, these reports are collected 
either from healthcare workers, patients or pharmaceutical companies. The data is 
then sent to the relevant regional or national centres for collation and evaluation. 
This information is then further analysed and forwarded to the WHO individual 
case safety report (ICSR) database – VigiBase. The national pharmacovigilance 
centres receive significant feedback since findings are promptly communicated to 
them by the WHO Collaborating Centre for International Drug Monitoring, Uppsala, 
Sweden (UMC) for appropriate action (WHO, 2015).  
The ICSR reporting to VigiBase is an important indicator to measure and analyse 
the national pharmacovigilance activities of countries (WHO, 2015). It is also 
important to realise that pharmacovigilance is not only focused on spontaneous 
ADRs and ICSR collections and submission, but it also encompasses activities 
such as medication errors, pharmacoepidemiological studies, clinical and product 
quality, products of compromised integrity, including counterfeit and substandard 
medicines (Ampadu et al., 2016; WHO, 2015). The rate of reporting varies 
significantly between underdeveloped, developing and developed countries, which 
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are more advanced and have enough resources to facilitate the process of ADR 
reporting (WHO, 2015). While in South Africa, being a developing country has only 
submitted a total of 28 609 reports to the VigiBase between 1992 and 2014 
(Ampadu et al., 2016).  
2.1.1 National level structures 
 
In 2010, WHO in consultation with its advisory committees agreed on the core 
minimum requirements that should be present for a functional national 
pharmacovigilance system, which included: 
• A national pharmacovigilance centre with designated staff, 
• A national spontaneous reporting system with an available national ADR 
reporting form, 
• A national database or system for collating and managing ADR reports, 
• A national advisory committee, that is able to provide technical 
recommendations on safety issues and regulatory actions, validate 
causality and evaluate risk; and when necessary, participate in crisis 
management including crisis communication, and, 
• A communication strategy that is clear for both routine and crises 
communication (Maigetter et al., 2015). 
To support and transform the activities of pharmacovigilance and enhance safety 
of patients, every country must have a national pharmacovigilance centre, with 
independent expertise to ensure that safety information on all available drugs is 
adequately collected, impartially evaluated and made accessible to all. Adequate 
nonpartisan financing must be available to support the system. Exchange of data 
and evaluations among countries must be encouraged and supported (Khan et al, 
2013; Jobson, 2003). 
In SA, the function of pharmacovigilance has been undertaken by the National 
Adverse Drug Events Monitoring Centre (NADEMC) at the University of Cape 
Town. The NADEMC was set up as a partnership between the MCC and the WHO  
(Joubert and Naidoo, 2016; Jobson, 2003). Figure 2.1 illustrates the flow of ADR 
information from individuals (i.e. healthcare professionals or customers) right 
through to decision making by the regulatory authorities and other involved 
stakeholders (SPS, 2010). 
https://etd.uwc.ac.za
Chapter 2: Literature Review 
 
9 
 
 
Figure 2. 1 The pharmacovigilance flow of information framework (adapted from SPS, 2010) 
Spontaneous reporting is essential for the identification of new signals and/or 
adverse drug reaction trends. This is supported by the use of a nationally available 
ADR reporting form as recommended by the WHO. South Africa is one of the 
many countries which have a national ADR reporting form (see Appendix 1). A 
previous study by Bandekar et al. (2010) assessed both the variables included on 
the form and the completeness of data capturing (Maigetter et al., 2015; 
Banderkar et al., 2010). Based on the results and recommendation of this study 
that ADR form was updated to include all 18 variables which are considered to be 
crucial in identifying and enabling appropriate assessment of the reported ADRs. 
These include patient details, description of the reaction and outcomes, 
dechallenge and rechallenge information, format of the form, encompassing the 
flow of information, adequate space and columns, etc. as per Table 2.1.  
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Table 2.1 Evaluation of the South African ADR reporting form (Banderkar et al., 2010). 
Criteria Available/Comment 
Patient’s information   
Pregnancy status X 
Allergic status   
Diagnosis   
Description of reaction   
With less space 
List of suspected drugs Six drugs, including concomitant 
medication 
Dose, frequency of drugs   
Space for concomitant drugs   
No separate space available, but 
included in suspected drug column 
Start date and stop date of suspected drugs   
Relevant history of patients   
Actions taken X 
Severity X 
Causality X 
Outcome   
Dechallenge X 
Rechallenge   
Treatment of ADR   
Lot no, expiration date X 
 
Pharmacovigilance (PV) should be a structured process with ongoing data which 
is vital to ensure safety and effectiveness of medicines and to provide information 
concerning regulatory actions such as drug safety alerts, labelling changes to the 
product information, drug recalls or withdrawal of a drug from the market (Palleria 
et al., 2013; Jeetu and Anusha, 2010). The process of pharmacovigilance may 
generate large volumes of data, with the cooperation of healthcare professionals in 
practice and this requires expertise from the pharmacovigilance centre in order to 
manage this data, respond and update the reporters and avoid uninformed 
discontinuation of a drug from the market (Jeetu and Anusha, 2010). 
The large volume of data generated through the process of pharmacovigilance 
needs to be collated via a national database or a system for collating and 
managing ADR reports (Maigetter et al., 2015). In South Africa, this function is 
carried out by the NADEMC, which manage the collection and evaluation of 
spontaneous ADR reports from the stakeholders (Mehta, et al., 2017). 
The WHO also advised on having a national advisory committee. South Africa has 
met this requirement by establishing a pharmacovigilance expert committee within 
the MCC in 2003. This committee is composed of a pharmacist and six external 
experts from various institutions (Maigetter et al., 2015). The role of this committee 
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was to advise on post-marketing related safety issues, review complaints, ADRs, 
make recommendations regarding registration conditions of medicine and to 
communicate actions to be taken for crisis management, as well as routine 
communication strategy that is clear for both customary and crises communication 
(Mehta et al., 2017; Maigetter et al., 2015). Communication must be prioritised to 
ensure the success and sustainability of pharmacovigilance. Poor communication 
and feedback are a major challenge and weakness to pharmacovigilance systems. 
It has been suggested that a national pharmacovigilance website should be 
established to facilitate information sharing amongst relevant stakeholders (Mehta 
et al., 2014). 
 
2.1.2 Facility based structures and processes and pharmacovigilance 
 
In addition to the overarching national pharmacovigilance systems discussed 
previously, the WHO has additionally advocated for the establishment of PTCs in 
healthcare institutions (WHO, 2003). The PTCs should be a multidisciplinary forum 
which includes prescribers, pharmacists, nurses, administrators, quality 
improvement managers and other healthcare workers involved in the medication 
use process (Tyler, et al., 2008). The main function of the PTC is to maximise and 
promote the rational use of medication. This role is achieved through the 
development and evaluation of medicine-related policies and procedures and 
advice on their implementation; assessment and selection of essential and vital 
medicines for the institution’s formulary on an ongoing basis to support continuous 
and sustainable access to medicines; monitoring and evaluation of medicine use, 
safety and quality; and to advise on the implementation of preventative and 
corrective action of ADRs, particularly those which are potentially avoidable and 
often predictable  (Vang et al., 2006; NDoh, 2015; Schatz and Weber, 2015). 
The national Department of Health has adopted the WHO’s approach to the 
promotion of rational medicine use by establishing a PTC in healthcare institutions. 
However, there is lack of policy detailing the standards of the structure, role and 
functions of this committee and consequently, this resulted in differences in the 
objectives and functioning of PTCs across facilities (NDoH, 2015). Nonetheless, 
these committees are empowered with the responsibility for decision making and 
coordinating in a hospital setting (NDoH, 2015). It is easier to maintain surveillance 
of ADRs in a hospital setting where there is a PTC available (Rishi, 2008).  
PTCs may elect a subcommittee which manage specific tasks within the facility. 
Strengthening Pharmaceutical Systems, (2012) stated that the establishment of 
subcommittees enhances simultaneous functioning of the main PTC, however 
there is no policy indicating which subcommittees should be appointed in the 
facilities. The PTC is expected to evaluate the needs of the institution and based 
on the speciality and expertise available, several subcommittees may be 
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appointed and these may include; antimicrobial stewardship, procurement 
advisory, pharmacovigilance, rational medicine utilisation, safety and quality 
committees, etc. (Strengthening Pharmaceutical Systems, 2012). 
 
2.2 Pharmacovigilance and patient care at a health facility 
 
Patient care is defined as services rendered by healthcare professionals for the 
benefit of a patient (Yorke, 2016). The process of patient care commences with 
the diagnosis - to determine the need for medical care, this could be an 
assessment of a symptom or a laboratory test or more complex investigations. 
Subsequent to the diagnosis, there should be planning, implementation and 
assessment of the treatment, this is known as the therapeutic process 
(Williamson, 1971). Quality and safety is of utmost importance in the diagnostic 
and therapeutic processes. Unfortunately, in everyday practice, not all patients 
receive the best care. There is often deprivation of care, unnecessary, outdated or 
even harmful care where there is overuse, underuse or misuse of care 
(Bodenheimer, 1999; Ward et al., 2017). There are various terms used to explain 
inappropriate care and adverse outcomes experienced by patients during 
diagnostic and therapeutic processes. Table 2.2 describes the most commonly 
used terms to describe inappropriate care (Andrews et al., 1997).  
Adverse drug events are described as any unpleasant medical incidents related to 
the use of a drug, rather than the underlying medical condition, which should be 
reported for the benefit of the public rather than the individual (Griffin and Resar, 
2009). The term adverse effect and adverse drug reaction are similar and both 
occur at any dose, however they are not synonymous. Adverse drug reactions are 
usually detected by clinical manifestations or laboratory investigations while 
adverse effects are not. It is, however important to distinguish the two from 
adverse drug event, which is directly linked to the injury or death of a patient, while 
adverse drug reaction and adverse effects are characterised by suspicion of the 
link between the drug and the reaction and includes all adverse events associated 
with the administration of a drug irrespective of the aetiology (Nebeker et al., 
2004). There are different types of aetiologies, and only a part of these are 
immune-mediated hypersensitivity reactions, while most are non-immune 
mediated and related to pharmacological properties of the medicine or individual 
predisposition  of the patient (Hausmann et al., 2012). 
Errors and medication errors are often confused, it is important to recognise that 
errors include medication errors, whereas medication error requires the 
administration of a drug. Negligence and malpractice are closely related terms 
which are usually incorrectly used interchangeably, in reality, malpractice is a 
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subcategory of negligence and it is considered to be more serious than negligence 
(Grober and Bohnen, 2005).  
The number of deaths resulting from medication errors has increased. This 
increase is not a surprised as in recent years, newer drugs have been introduced, 
medical care has become more complex and specialised and the population has 
aged (Aronson, 2009). An important strategy on how to improve errors in health 
care was to identify medication errors regardless if they were associated with an 
adverse event or not, hence strengthening pharmacovigilance. Safety advocates 
have made a recommendation to identify and report all adverse events, 
irrespective of whether or not they are associated with harm as this will lead to a 
safer environment of patients (Naessens et al., 2009). 
The definition of pharmacovigilance has been expanded to include: Herbals, 
traditional and complementary medicines, blood products, biologicals, medical 
devices and vaccines (WHO, 2004). Many other issues are also of relevance to 
the science of pharmacovigilance: substandard medicines, medication errors, 
reports of lack of efficacy, use of medicines for indications that are not approved 
and for which there is inadequate scientific basis, case reports of acute and 
chronic poisoning, assessment of drug-related mortality, abuse and misuse of 
medicines, adverse interactions of medicines and food (Jobson, 2003). 
Table 2.2 Terms used to describe inappropriate patient care and adverse outcomes 
Term Definition 
Medication Errors Failures in the process of therapeutic care, that did not proceed as 
intended and is not directly linked to harm, an example is when the 
doctor’s prescription is misread or a dangerous dose is administered 
to a patient 
Adverse drug 
events 
Noxious and unintended drug effects, occurs at therapeutic doses for 
prophylaxis, diagnoses, therapy, or modification of physiologic 
functions and are directly linked to harm done by the drug rather than 
the disease 
Adverse event Any negative or harmful occurrence that takes place during treatment, 
which may or may not be associated with a medicine. Note. A fall 
could be such an event that may – or may not – have any association 
with a medicine. 
Adverse effect Related to the use of a drug leading to dangerous, unintended 
reactions, it also includes medication errors and commonly referred to 
as ‘side effect’. Some adverse effects may occur during initiation, 
dose-adjustments or discontinuation of treatment. Unlike adverse drug 
events, adverse effects occur at any dose and can be foreseen by 
healthcare workers. The main difference between adverse effect and 
adverse drug reaction is that the latter is usually detected by clinical 
investigations and laboratory tests  
Adverse drug 
reaction 
Indicates a response to a medicinal product which may be toxic or 
used accidentally. This also includes overdose, misuse, abuse and 
lack of efficacy of a drug used. They differ from adverse effect 
because they are usually detected by clinical manifestations (signs 
and symptoms) 
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Term Definition 
Mal-occurrences When an individual does not respond well to a drug or experiences an 
adverse reaction as a result 
Complications An unexpected result which occurs subsequent to a treatment, 
medical procedure or illness. It is termed so because it ‘complicates’ 
the situation 
Medical Injuries Harm or hurt to the body, that may result in a prolonged hospital stay, 
disability or death 
Errors An unintended act by a healthcare worker, which results in unintended 
outcomes, these include omissions 
Negligence Preventable adverse events or failure to meet the minimum standard 
of care 
Mal-practice An act or omission which varies from the defined norms of practice 
and cause injury to the patient, this term is closely related to 
negligence 
Harm Unintended physical injury resulting from or contributed to by medical 
care that requires additional monitoring, treatment or hospitalisation, 
or that result in death 
Near Miss Errors that did not result in injury to the patient but could have resulted 
in adverse consequences. Also referred to as potential adverse events 
or close calls 
(Griffin and Resar, 2009; WHO, 2003; Naessens et al., 2009; Grober and Bohnen, 2005; 
La Pietra et al., 2005; Gagnon et al., 2012; Nebeker et al., 2004) 
 
ADRs are classified into six (A, B, C, D, E and F). A -  (augmented) dose related, 
B – (bizarre) non-dose related, C – (chronic) dose - and time – related, D – 
(delayed) time-related, E – (end of use) withdrawal and F – (failure) lack of efficacy 
or failure of treatment (Edwards and Arson, 2000). Other sources classify these 
reactions into two, namely type A reactions and type B reactions. Type A reactions 
are predictable reactions since they relate to the dose and chemical processes for 
which they are understood, they also known as pharmacological reactions, while 
type B reactions are not well understood and are unpredictable and not related to 
the dose, they are also referred to as idiosyncratic reactions. Some people 
experience these idiosyncratic reactions as allergic reactions due to their genetic 
makeup (Edwards and Arson, 2000; Rawlins and Thompson, 1991). 
 
2.3 Factors affecting ADR reporting in health facilities 
 
Prescriptions are usually written by doctors and clinical nurse practitioners in the 
public health primary health care sector. However that does not mean that they 
are solely responsible for pharmacovigilance. Pharmacists and nurses have a vital 
role in recognizing, evaluating, monitoring and reporting drug related problems to 
generate knowledge on undesirable drug effects at individual and population level 
(Toklu et al., 2016). 
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An observational study conducted in India has outlined that underreporting of 
ADRs is fuelled by the fear of litigation, lack of knowledge and inability to 
recognize these events, ignorance, lack of financial incentives, time constraints 
and the belief that other healthcare workers should be the ones to report the ADR 
(Khan et al., 2013). Underreporting is a great concern and has a negative impact 
on public health, limiting the identification of risk and further assessment of 
monitoring drug efficacy and safety post-marketing (Mazzitello et al., 2013; Alsbou 
et al., 2017). 
The concern with underreporting and drug safety is fuelled by the fact that South 
Africa has the world’s highest roll-out of antiretroviral drugs (ARVs), with the 
highest tuberculosis incidence globally (UNIADS, 2013; WHO, 2013). The 
concurrent use of ARVs and other treatment to manage or prevent opportunistic 
infections places the patients at greater risk of adverse drug reactions (Mouton, et 
al., 2015). In a resource limited country like South Africa, these reactions are not 
reported (Mouton et al., 2015). Several attempts have been proposed to improve 
pharmacovigilance activities with minimal success, and no one is willing to take 
this responsibility (Khan et al., 2013). 
The attempts which have been made to improve ADR reporting include 
educational interventions and refresher courses on ADRs for healthcare 
professionals who are presently working, including pharmacovigilance in 
undergraduate training, establishment of an ADR committee, encourage all 
healthcare workers to report all suspected ADRs, irrespective of the level of 
seriousness, increasing the awareness of national pharmacovigilance 
programmes while countries such as India have modified its ADR reporting form to 
make it easier for the healthcare professional to fill-in, with clear objectives on 
what to report (Khan et al., 2013). 
Table 2.3 was adapted from a questionnaire based cross-sectional study done by 
Khan et al in 2013 to investigate the knowledge and attitudes of doctors to ADR 
reporting and it shows the long-term and short-term interventions to promote 
spontaneous ADR reporting. The results highlighted some of the short-term 
measures which will improve reporting, which included raising awareness, 
encouraging reporting and training healthcare workers on pharmacovigilance. 
Long-term measures included nominating a person dedicated specifically for 
pharmacovigilance, improving the ADR form to make it more concise, teaching 
pharmacovigilance in universities as well as providing feedback on past reports to 
highlight the significance of reporting (Khan et al., 2013) 
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Table 2.3 Short and long–term interventions to promote spontaneous ADR reporting (Khan et al., 2013; 
Aronson, 2009). 
SHORT-TERM  MEASURES LONG-TERM MEASURES 
Raise awareness of ADR reporting Have someone solely for ADR reporting, 
like an ADR reporting champion in the 
hospital 
Encourage reporting of all suspected 
ADRs, regardless of the level of association 
with the interventions 
Minimise administrative work, by making 
ADR forms more concise and objective on 
what to report as well as introducing 
computerised systems 
Training in PV, emphasizing the risk 
perceptions of medicines. Including newly 
marketed drugs, over-the-counter drugs, 
herbals, traditional and complementary 
medicines 
Change attitudes through discussions and 
trainings, where ADR reporting is seen as 
an integral part of medical practice. There 
should be a blame-free and non-punitive 
environment, provide feedback as well on 
past reports to illustrate its importance 
Encourage the reporting of all suspected 
ADRs, whether known or unknown, 
common or uncommon, serious or non-
serious 
Pharmacovigilance should be an important 
part in undergraduate and post graduate 
curricula and not be an elective  
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3. CHAPTER 3: METHODOLOGY 
 
3.1   Study design 
This study was an exploratory, multicentre study. A structured questionnaire with 
closed and open-ended questions was used for data collection. Figure 3.1 
provides a schematic representation of the process.  
 
 
Figure 3.1 An overview of the research process 
 
3.2   Study setting 
There are nine provinces in South Africa, with the Gauteng province being a 
densely populated urban area with approximately 13.2 million people contributing 
to 24% of the South African population. Approximately 71.8% of Gauteng’s 
population was reliant on the government for healthcare services in 2015, this 
number has increased from the 66% reported in 2008 (GDoH, 2016). There are 11 
district hospitals, nine specialised hospitals, nine regional hospitals, three tertiary 
hospitals and four central hospitals (GDoH, 2016).This study was conducted in 
regional and district public hospitals, which fall under the five districts, namely City 
of Johannesburg, City of Tshwane, Ekurhuleni, Sedibeng and West Rand, situated 
in the Gauteng province as shown on the Figure 3.2.  
Obtained clearance from University of the 
Western Cape Biomedical Research and Ethics 
committee
Registered the research project at the National 
Health Research Database (NHRD)
Obtained permission to conduct the study from the 
respective hospital CEOs and in some cases, from 
the district committee
Conducted a pilot study at Far East Rand 
regional hospital, in Ekurhuleni district
Initiated data collection using 
the data collection sheet
Captured data 
electronically
Used descriptive statistics 
to analyze data and 
measured the outcomes
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The districts include; the City of Johannesburg Metropolitan Municipality, 
Ekurhuleni Metropolitan Municipality, City of Tshwane Metropolitan Municipality, 
West Rand District Municipality and Sedibeng District Municipality (GDoH, 2016). 
Tertiary, central and specialised hospitals were excluded. The reason for this 
exclusion was mainly because these three types of hospitals usually have systems 
in place which are only applicable to their facility and cannot be applied elsewhere 
(South Africa, 2012; GDoH, 2016). In addition to this, tertiary and central hospitals 
are linked to universities which consistently evaluates, monitors and implements 
new systems (South Africa, 2012). 
 
 
Figure 3.2 Gauteng province district map 
3.3   Study site selection and target population 
3.3.1   Study site selection 
All the regional (n=9) and district (n=11) public hospitals situated in the Gauteng 
province were included. Stratified non-random sampling was employed to select 
the sample of regional and district hospitals in each of the five districts. The 
following inclusion and exclusion criteria were applied: 
3.3.1.1   Inclusion criteria 
• All regional and district public hospitals within the Gauteng Province. 
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3.3.1.2   Exclusion criteria 
• Specialised, tertiary and central hospitals were excluded as they usually have 
systems in place which are unique to their particular setting, and, 
• Clinics, community healthcare centres and regional pharmacies, irrespective of 
being state or privately owned and being within the Gauteng province. 
The stratified non-random sampling used in this study is defined as sampling 
drawn from a population, which is divided into several groups or ‘Strata’ (Neyman, 
1934). The strata in this study was the Gauteng health districts, which each 
contained both regional and district hospitals. The researcher sent out permission 
letters to all the facilities and selection was done on a first response first selected 
basis for each particular district. The selection process also provided that both 
regional and district hospitals be presented in each district. All the facilities had 
equal opportunity to be selected, because all invitations were sent out 
simultaneously. For logistic purposes, a target sample of about 50% of the 
hospitals was set to participate in the study. 
 
3.3.2   Target population and recruitment 
Access to each selected facility was acquired through the submission of a letter of 
intent (Appendix 2) to the hospital chief executive officer (CEO). The CEO was 
requested for permission to access the facility and assist with the identification of 
the person(s) to be interviewed. The target population for interviews included any 
health care personnel employed at the selected facilities and involved in facility-
based pharmacovigilance activities and in particular ADR reporting. Preference 
was given to interview nominated persons for pharmacovigilance or ADR reporting 
in the facility.  
In cases where more than one person were identified to be interviewed, all were to 
be interviewed and data collated for that particular facility. In cases where it would 
be difficult to identify person(s) for the interview, the PTC representative or the 
pharmacovigilance subcommittee would be approached. In cases where the 
hospital did not have any of these committees, the pharmacy manager or 
supervisor would be interviewed as they were expected to be part of the 
multidisciplinary team of the PTC, together with nurses, quality-improvement 
managers, physicians and other healthcare professionals and staff who participate 
in the medication use process. 
An appointment was set up with the person(s). The study information sheet 
(Appendix 3) and data collection sheet (Appendix 4) was sent to each person prior 
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to the interview in order for them to prepare for the questions that would require 
them to go through the facility’s pharmacovigilance records. 
3.4    Data collection 
On the day of the interview, data collection commenced subsequent to the signing 
of the informed consent form (Appendix 5) by the interviewee after they had time 
to ask questions about the study. In addition to the interviewer taking field notes of 
the interview, an audio recorder was used to ensure the capturing of complete 
information.  
The data collection instrument was a questionnaire which was developed by the 
researcher and adapted from the following studies: Toklu et al., 2016; Hadi et al., 
2017. The questionnaire contained three sections; A, B and C. Section A was 
designed for facilities that had a nominated person(s) for pharmacovigilance, or, a 
subcommittee responsible for pharmacovigilance, while section B was for facilities 
which did not have a nominated person(s) or subcommittee for pharmacovigilance. 
Section C was compulsory for all facilities.  
Section A of the questionnaire generated information regarding the nominated 
person or committee, the type of pharmacovigilance training that these persons 
had and details on the, the types and frequency of ADRs recorded and reported. 
Section B collected information on the reason the facility did not have a nominated 
person or committee for pharmacovigilance, process which was followed for ADR 
reporting and if there were any plans to nominate a person or committee in future 
for pharmacovigilance. Section C gathered information on pharmacovigilance 
documents used and produced by the facility. This included examples of the ADR 
report form, algorithms used to identify ADRs, ADR reports, challenges to ADR 
reporting and /or committee meeting agendas and minutes. 
Data collection extended over a period of six weeks, and was captured 
electronically to be analysed. The data collection process is illustrated in Figure 
3.1. 
3.5   Pilot study 
Prior to commencement of data collection, following ethical approval of the study, 
the data collection instruments were pilot-tested at a regional hospital located at 
Ekurhuleni district to determine the reliability and validity of the data collection 
tools and familiarise the researcher with the data collection process. This aided the 
researcher with obtaining an overview of the actual study in terms of how the 
interviewees interpreted and responded to the questions, the type of responses 
received as to how they address the aims and objective of the study, and 
ultimately assisted in making the necessary changes to the data collection 
instruments, as well as improve the questionnaire. The researcher had the 
opportunity to evaluate whether the questions were appropriate to elicit the desired 
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information based on the results of the pilot study. Subsequent to the pilot study, 
there were no changes made to the data collection instruments. The data that 
were collected from the pilot site were not used in the findings of this study. 
3.6   Data capturing and analysis 
The closed-ended question responses were captured on a Microsoft Excel™ 
spread-sheet and were checked for accuracy by an independent master’s 
graduate. Quantitative data from Microsoft Excel™ was analysed using descriptive 
statistics functions. Categorical variables were summarised by frequency counts 
and percentages. 
The open-ended question responses were transcribed verbatim from the audio 
recordings of the interviews. These transcriptions were sent to the participant for 
verification and any further explanations that might not have been clear on the day 
of the interview. The qualitative data were coded and thematically analysed. 
3.7   Reliability and validity of data 
Reliability is the extent to which results are consistent over time or a consistency 
of a measurement, or the degree to which an instrument measures the same way 
each time it is used under a similar methodology. In short, it is the repeatability or 
reproducibility of a measurement (Golafshani, 2003). Validity refers to the extent to 
which a research design is scientifically sound or appropriate (Struwig and Stead, 
2013). Validity can be either internal or external. Internal validity refers to the 
extent to which the study design and data obtained allowed the researcher to draw 
accurate conclusions about the associations within the data (Leedy and Ormrod, 
2001). External validity refers to the extent to which the results obtained during the 
study could be generalized to other contexts (Leedy and Ormrod, 2001). The 
validity of the data collection form was increased by the pilot study, which was 
conducted prior to the commencement of the study. Reliability and validity of the 
data was ensured by using the same data collection tool for the whole period of 
this study.  
3.8   Bias 
Bias is defined as any tendency that prevents unprejudiced consideration of a 
question. In research, bias occurs when one outcome or answer over another is 
selected by introducing systematic error into sampling or testing. Bias can occur at 
any phase of research, including study design or data collection, as well as in the 
process of data analysis and publication (Pannucci and Wilkins, 2010). In this 
study, bias was minimised as the data collection sheet was filled together with the 
respondent(s) and the researcher did not, under any circumstance, alter the 
response once the interview has ended. The transcripts were sent to the 
participants for verification and they had an opportunity to address any 
inaccurately captured information.  This means that the researcher’s views and 
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preferences did not factor in the data collected. The protocol methodology was 
strictly followed and there were no deviations without prior approval. 
3.9   Ethical considerations 
Ethical approval was obtained from the University of Western Cape Biomedical 
Research Ethics Committee (BM18/6/15). A letter of intent to conduct the study at 
a particular facility was submitted to each of the hospital’s chief executive officer 
(CEO) and respective districts research committees for permission to gain access 
to the hospitals following the Registration of the research project at the National 
Health Research Database (NHRD ref: GP_201808_041), which serves as a 
repository of health-related research conducted in South Africa. Furthermore, 
some district hospitals required approval of a committee in addition to the CEOs 
permission. The hospital CEOs were requested to assist in identifying health care 
workers in the facility who were involved in pharmacovigilance or ADR reporting 
for the facility. Subsequent to the identification of potential interviewees, an 
appointment was set up with the person(s). The study information sheet (Appendix 
3) and data collection sheet (Appendix 4) was sent to each person prior to the 
interview in order for them to prepare for the questions that would require them to 
go through the facility’s pharmacovigilance records. 
When considering the principles of autonomy, the participating hospital facility 
pharmacovigilance representatives were duly informed about the intentions of the 
study subsequent to the administration of the study information sheet (Appendix 3) 
together with the informed consent (Appendix 4) which were signed once the 
participants were assured of confidentiality and that they were able to withdraw 
from the study at any time, without any consequences for them and they knew 
what was expected of them. The identities of the facilities were blinded by referring 
to the facilities using codes, this was to ensure that the reputation of the facility 
was not at stake.  
The signed consent forms with the identifying information were kept separate from 
the data collection sheets and were available only for senior researchers involved 
in the study. After the study is completed i.e. research reports and publications 
written, the electronic databases and paper data collection tools will be deleted 
and destroyed by the principal researcher. 
The risks for study participants were minimal as the anonymity protection ensured 
confidentiality. No direct benefits for the study participants were anticipated.
https://etd.uwc.ac.za
Chapter 4: Results 
 
23 
 
4. CHAPTER 4: RESULTS  
 
4.1 Gauteng Public Hospitals 
 
The data collection process started in August 2018, and it was spread over a 
period of six weeks, until October 2018. Only public sector hospitals situated in 
one of the following five districts in the Gauteng province were included in this 
study.  
 
Table 4.1 Gauteng Province districts and regional hospital totals and those that participated in the study 
District Regional Hospitals 
Number (participated) 
District Hospitals 
Number (participated) 
West-Rand District Municipality 1 (1) 2 (1) 
City of Johannesburg Metropolitan 
Municipality 
2 (1) 2 (1) 
Ekurhuleni Metropolitan Municipality 4 (2, 1*) 1 (0) 
City of Tshwane Metropolitan 
Municipality 
1 (1) 4 (2) 
Sedibeng District Municipality 1 (1) 2 (1) 
Key: * pilot site 
Table 4.1 illustrates the districts and number of hospitals situated in each district, 
where the facilities used in the study are indicated in brackets. There were 11 
district hospitals spread over the five districts in the province of which five (45.5%) 
were selected for this study using stratified non-random sampling. Similarly, there 
were nine regional hospitals which were spread over the five districts of the 
Gauteng province. From the nine regional hospitals, six (66.7%) were selected for 
participation in this study and one was used as the pilot site. The pilot site’s results 
were excluded from the study.  
 
4.2 Hospitals that had a person(s) or committee nominated for ADR 
reporting 
 
Five (45.5%) of the 11 hospitals had either a person or committee nominated for 
ADR reporting. This was spread over two (33.3%) of the regional hospitals and 
three (60%) of the district hospitals as shown on Table 4.1. All the hospitals 
indicated that their nominated persons were pharmacists as depicted in Table 4.2.  
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Table 4.2 Availability of person(s) or committee responsible for pharmacovigilance 
Is there a person or committee nominated for 
adverse drug reactions reporting District Hospital Regional Hospital 
Yes 3 2 
No 2 4 
 
Table 4.3 Facilities which had a nominated person(s) or committee responsible for pharmacovigilance 
 
 
4.2.1 Knowledge on ADR reporting and confidence in the ability to identify 
ADRs 
 
Table 4.3 demonstrates the self-reported knowledge on ADR reporting and 
confidence to identify an ADR of the persons nominated for ADR reporting. The 
Likert-scale was used to determine whether their ratings were poor, fair, average, 
good or excellent. One pharmacist rated his/her knowledge on ADR reporting as 
average, while two pharmacists rated their knowledge as good and another two as 
excellent. The same respondents rated their confidence in identifying an ADR as 
 District (n=3) Regional (n=2) 
The qualification of the nominated person 
• Pharmacist 
 
3 
 
2 
Knowledge of ADR reporting 
• Average 
• Good 
• Excellent 
 
1 
1 
1 
 
0 
1 
1 
Confidence to identify an ADR 
• Average 
• Good 
• Excellent 
 
1 
1 
1 
 
1 
0 
1 
Received any pharmacovigilance training 
• Yes 
• No 
 
2 
1 
 
2 
0 
When was pharmacovigilance training received 
• Within the last 12 months (2017) 
• 1-2 years ago (2015-2016) 
• More than 2 years ago (before 2015) 
 
0 
2 
0 
 
1 
0 
1 
Was the training adequate 
• Yes 
 
2 
 
2 
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average (2 participants), good (1 participant), and excellent (2 participants), 
respectively. 
 
4.2.2 Pharmacovigilance training of persons nominated for ADR reporting 
 
Four (80%) of the nominated persons for ADR reporting indicated that they had 
training on pharmacovigilance as depicted in Table 4.3. All four respondents who 
had training stated that the training which was received was adequate. One of the 
respondents last received training on pharmacovigilance in 2017, two in 2016, 
while the other received it in 2014. Training was received from the following 
providers; Johannesburg district, Right-to-care, National Department of Health 
(nDoH) National Road Show and Pulse Health Solution. One of the nominated 
persons for ADR reporting completed a master’s degree in ADR reporting, where 
she implemented new strategies to improve ADR reporting. Only one person 
nominated for pharmacovigilance had not received any pharmacovigilance 
training, because she was only recently appointed for this role. Those who 
received training on pharmacovigilance stated that the training included ADR 
reporting, how to report, how to identify ADRs, who should report, why reporting is 
done, as well as medication errors.  
4.2.3 Previously reported ADRs by nominated person for ADR reporting 
 
All the nominated persons provided a file containing all the ADR reporting 
documentation for their facility. The number of identified and reported ADRs over 
the past 12 months in each hospital was obtained by going through the files which 
were provided. The district hospital, HOSD1 did not identify nor report any ADRs, 
HOSD2 had five ADRs, while HOSD3 had three ADRs. All the district hospitals 
(HOSD1, HOSD2 and HOSD3) did not have any deaths due to ADRs, while the 
regional hospitals (HOSR1 and HOSR2) had 10 and 199 ADRs identified and 
reported over the past 12 months respectively. Whereas in the hospital HOSR1 
had 1 death - where streptokinase IV was the cause, while hospital HOSR2 had 
less than 10 deaths due to ADRs, the exact number could not be confirmed as 
there were patients who were not followed up.  
4.2.4 Feedback from committees on reported ADR 
 
All facilities had a Pharmacy and Therapeutics Committees (PTC), which are 
audited annually as per the requirements of the national core standards. Only two 
(40%) of the five hospitals that had a person nominated for pharmacovigilance 
indicated that they received feedback from either their institutional 
pharmacovigilance or antimicrobial stewardship (AMS) subcommittees of the 
hospital PTCs, respectively. The hospital with the AMS committee, only provided 
feedback on ADRs caused by antimicrobials, i.e., antibiotics, antifungal, 
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antiparasitic or antiviral agents. The subcommittees in both these institutions met 
monthly.  
The functions of the pharmacovigilance subcommittee was to set the norms and 
monitor medication errors, adverse drug events and poor product quality use in 
order to promote rational medicine use and the safety use of pharmaceutical 
products, blood and blood products; to develop and implement protocols and 
guidelines regarding the prevention and reporting of medication errors and 
adverse drug events; to conduct regular audits on the reporting of medication 
errors and adverse drug events; and to provide feedback and other appropriate 
measures in order to correct safe and effective use of pharmaceutical products, 
blood and blood products. The function of the AMS subcommittee was to draft 
antibiotic policies which will improve quality of patient care and safety, reduce 
antimicrobial resistance, optimise therapy, reduce adverse effects and treatment 
failures, with increased cure rates, manage adverse events related to the use of 
antimicrobials, implement infection control practices and provide feedback to the 
hospital PTC.  
 
4.3 Hospitals that did not have a person(s) or committee nominated for 
ADR reporting 
 
There were six hospitals that did not have a person(s) or committee nominated for 
ADR reporting, the hospital CEOs recommended that the pharmacy managers 
complete the study questionnaires, because the hospitals’ ADR forms were sent to 
the pharmacy following the identification and reporting of an ADR. No other 
healthcare personnel were identified for the purpose of ADR reporting and it was 
decided with the CEO and the pharmacy managers that only the pharmacy 
managers would participate in the study.  
The hospitals were asked for reasons for not having a nominated person or 
committee for ADR reporting and most of the hospitals stated that there is a lack of 
volunteers for this role: 
“There is no one to take the initiative and no one wants to volunteer.” – HOSD5 
Shortage of staff was also one of the prevalent reasons for not having a committee 
or a person for ADR reporting, hospital HOSR4 stated that “The burden is high 
and there is not enough staff“. Similarly, the hospitals expressed that the rate of 
reporting is low and therefore there is no need to have such a person or committee 
as stated by HOSR6.  While hospital HOSR5 believed that there is no need for 
such a person or committee, and said “it is supposed to be everyone’s 
responsibility“. The hospitals also stated that there are too many committees and 
they do not want to add more, they are waiting for a directive from National to 
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instruct them to form this specific committee or nominate such a person, there is 
lack of time, training and resources to support this particular function, while 
HOSD5 also added that “it is not remunerated and it is too administrative”.  
None of the hospitals had attempted to nominate a person or committee for ADR 
reporting in the past. Only one of the six hospitals had plans to nominate a person 
or a committee for ADR reporting in future, and this person was the store 
pharmacist. 
4.3.1 The process of ADR reporting 
The hospitals which did not have a person nominated for ADR reporting were 
asked to describe the steps which they follow when ADRs have to be reported and 
the various description are stated below:  
4.3.1.1 The process of reporting for HOSD4 
There were ADR reporting forms available in the wards which were kept in a 
designated box. Once an ADR was identified, the doctor had to complete the form 
or instructed the assisting nurse to do so. After the form had been completed, they 
were either taken to any of the PTC members, to the pharmacy or they were left in 
a designated box where a pharmacy staff member collected the forms and took 
them to the pharmacy. They would then be discussed in the hospital PTC and then 
scanned by the pharmacy manager and forwarded to the district office. The district 
office would then send these forms to SAHPRA.  
4.3.1.2 Process of reporting for HOSD5 
The nurses in the wards were expected to identity the ADRs since they were the 
ones who administered medicine to the patient. Once an ADR was identified, an 
ADR reporting form would be completed and sent to the pharmacy manager who 
took them to the PTC for discussion. The infection control committee was 
consulted if there were any antimicrobials involved. Following the PTC discussion, 
the forms were sent to SAHPRA using the email address provided on the forms.  
4.3.1.3 Process of reporting for HOSR3 
This hospital was able to provide an algorithm which they used to identify ADRs. 
Only serious ADRs were reported to the CEO, who reported to the provincial 
quality assurance director within 24 hours via Short Message Service (SMS). The 
serious adverse drug reactions are those which results in death, life threatening 
experience or require hospitalisation or prolongation thereof. The CEO would then 
initiate an investigation through the Serious Adverse Drug reactions committee of 
the district (City of Johannesburg). A preliminary report would be sent by the CEO 
within seven days to the Head of the Department that reported the ADR. Within 25 
days, a comprehensive QA investigation report was to be submitted. The Serious 
Adverse drug Event (SAE) was then either closed or referred to NADEMC and for 
ratification by the province. This algorithm is provided as appendix 9.  
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4.3.1.4 Process of reporting for HOSR4 
ADRs were reported from the wards/pharmacy using the national ADR reporting 
forms. These forms were then submitted to the pharmacy manager who would 
include them in the agenda for the PTC, as this also formed part of quality 
assurance. The ADRs would then be discussed in the PTC and a resolution made. 
Feedback would then be given to those who reported the ADR. The forms would 
then be sent to SAHPRA via email. 
4.3.1.5 Process of reporting for HOSR5 
In this hospital, following the identification of an ADR, doctors and nurses would 
bring the forms to the pharmacy. The pharmacy manager collated these forms, 
added ADR’s to the agenda for the PTC and they were discussed in the PTC and 
simultaneously sent to the provincial district and to SAHPRA. 
4.3.1.6 Process of reporting for HOSR6 
In this hospital, following the identification of an ADR, the treating doctor 
completed the national ADR form and sent them to the pharmacy manager, who 
worked closely with the pharmacy store supervisor and together they collated the 
forms received and added them to the agenda for the PTC to be discussed and 
concurrently sent the forms to the provincial PTC. If it was a quality issue, the 
query was sent to the medical supplies depot and included the batch number of 
the concerned product. The medical supplies depot then forwarded the query to 
the respective company, samples were retained in the pharmacy stores in case a 
sample was requested for testing. 
The processes described above have similarities, even though the order might be 
different. ADRs were identified, the ADR reporting form completed and submitted 
to the pharmacy manager. The pharmacy manager ensured that the ADRs were 
reported to the facility PTC and in some cases the provincial PTC. Depending on 
the hospital resources which were available, some hospitals did not send their 
reports to the provincial PTC as they were able to make resolutions within the 
facility’s PTC. The pharmacy manager also sent these forms to SAHPRA which 
reviews the reported ADR. None of the hospitals reported that they sent their ADR 
reports directly to the National Adverse Drug Event Monitoring Centre (NADEMC) 
Which is a unit of SAHPRA established to assist with the collection and 
management of the national ADR database (Maigetter, et al., 2015; Mehta, 2011). 
4.4 Status of ADR reporting at all participating hospitals 
4.4.1 Adverse Drug Reaction reporting forms 
 
The responses from the hospitals with a person or committee responsible for ADR 
reporting were compared with those without a person or committee responsible for 
ADR reporting. All the hospitals (n=5) with a person/committee responsible for 
https://etd.uwc.ac.za
Chapter 4: Results 
 
29 
 
ADR reporting reported that they used the national ADR reporting forms, while five 
(80%) of the hospitals without a person or committee responsible for ADR 
reporting were using the national ADR reporting forms. The only hospital that did 
not use the national ADR form, rather used a nurses’ incident report to record and 
report ADRs (Appendix 9). The reason why they were not using the national ADR 
reporting form was because the incidence report form was more comprehensive 
and less restricting; it also covered other non-treatment related aspects that were 
related to patient care. This hospital decided not to have too many forms and 
rather used one form which had enough space for the reporter to narrate the 
report/incident.  
All the hospitals reported that they kept the ADR reporting forms either at the 
pharmacy and in the wards or consulting rooms, as demonstrated on Table 4.4. In 
addition, all healthcare professionals had access to the forms, except for Hospital 
HOSR3, where only nurses had access. This was also the only hospital which did 
not use the national ADR reporting form. 
To verify the use of the national ADR reporting forms, hospitals were asked to 
produce at least three of the previously completed ADR forms for the researcher to 
view. All hospitals were able to produce these and they were using the latest 
version (version 4.0 07/16), with the exception of hospital HOSR3, which did not 
use the national ADR reporting form. However hospital HOSR3 was able to 
provide the researcher with a blank form used in the facility.     
Table 4.41 Status of ADR reporting at all participating hospitals (n=11) 
 Facilities with a 
nominated person 
(n=5) 
Facilities without a 
nominated person (n=6) 
Use of national ADR reporting form   
• Yes 5 5 
• No 0 1 
Where are the ADR reporting  
forms kept 
  
• Consulting areas  2 0 
• Pharmacy and wards 3 4 
• Wards only 0 2 
Who has access to the ADR 
reporting forms 
  
• All healthcare personnel 5 5 
• Nurses only 0 1 
Use of ADR trigger tools/ 
algorithms 
  
• Yes 1 1 
• No 4 5 
ADR reporting  in the facility is:   
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4.4.2 Use of algorithms and trigger tools for ADR identification and reporting 
 
Only two (18.2%) hospitals used algorithms and/or trigger tools to identify ADRs, 
one of these had a person/committee responsible for ADR reporting and the other 
one did not. Hospital HOSR3 was using the serious adverse drug events (SAE) 
algorithm, where following the identification of a SAE, they would immediately 
complete an incident report and inform the person in charge or operational 
manager, who would then report to the CEO, this report would escalate to the SAE 
committee who would then provide a resolution back to the CEO. The second 
hospital which used an algorithm/information poster was HOSR2, this hospital had 
a person responsible for ADR reporting. The algorithm/information poster 
contained information on what an ADR was and how to recognise an ADR, as well 
as the contact details of the person responsible for ADR reporting. This hospital 
had by far the highest reported number of ADRs (n=199), followed by hospital 
HOSR3 which had a total of 10 reported ADRs over the past 12 months, making it 
the second highest.  
4.4.3 Commonly reported ADR types 
 
All respondents allowed the researcher to go through the facility files that 
contained the documentation of the facilities’ ADR reporting activities for the past 
12 months (October 2017 and October 2018). The documentation consisted of 
completed ADR forms and reports with a notable absence of feedback reports 
from any committee or SAHPRA. The individual reported ADRs were first 
classified into categories which included administration errors, allergic reactions, 
quality issues, endocrine effects and others. These types were then assigned per 
facility to identify those ADR types which were most frequently reported across 
facilities (the unit of analysis in this study was thus the facility). The most 
frequently reported ADR types identified across facilities is summarised in Figure 
4.1. The most frequently identified ADR type reported at participating facilities was 
allergic reactions, reported by eight of the facilities, which presented as 
angioedema and rash. Two of these facilities had a nominated person for ADR 
reporting. Other frequently reported ADR types at facilities without a nominated 
person or committee included quality issues (n=3) and administration errors (n=2). 
The hospitals described administration errors as any deviations from the written 
prescription and included administering the wrong dose, wrong medicine, omission 
• Compulsory 3 5 
• Voluntary 2 1 
• Remunerated 0 0 
Facilities able to provide three 
completed ADR reporting forms 
  
• Yes 5 6 
• No 0 0 
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of medicines, using the incorrect route of administration, reconstituting with the 
wrong diluent/solvent/additive, or administering at the wrong time. Quality issues 
included deteriorated medicine, impurities present in the medicine, faulty 
packaging, incorrect tablet count or volume of medicine.  
Gynaecomastia was reported at two facilities which had a person or committee for 
ADR reporting, while the following reactions were reported at one facility and they 
included CNS effects, visual effects, gastrointestinal effects, cough and fatigue.  
 
Figure 4.1 Frequently reported ADR types in hospitals with (n=5) and without (n=6) a nominated person for 
ADR reporting over the past 12 months 
4.4.4 Most commonly reported class of drugs 
 
Figure 4.2 illustrates the most frequently reported drug classes implicated in 
previously identified and categorised ADR types in the facilities over the past 12 
months. ADRs due to antiretroviral drugs (ARVs) were prevalent in eight of the 11 
hospitals. Five of these hospitals did not have a person or committee for ADR 
reporting. The second most common class of drugs to produce ADRs was ACE 
inhibitors (n=5). Enalapril was by far the most frequently prescribed ACE inhibitor 
at these facilities. There were two Central nervous system (CNS) drugs at 
hospitals with a person or committee for ADR reporting as shown on the Figure 
4.2 and these included anticonvulsants, while hospitals without a person or 
committee for ADR reporting had anaesthetics and antipsychotics under the CNS 
drugs. Other drugs included reports on lubricants (KY Jelly), antibiotics and 
streptokinase which resulted in death of a patient. All of these reported cases 
never received any form of feedback from SAHPRA. 
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Figure 4.2 Commonly reported drug classes causing ADRs in hospitals with (n=5) and without (n=6) a 
nominated person for ADR reporting 
4.4.5 Challenges with ADR reporting in the facilities 
 
Table 4.5 lists some of the challenges associated with ADR reporting which were 
reported by the facilities. The most common challenge for facilities with and 
without a nominated person for ADR reporting was prevalent ADRs not being 
reported. The second most common challenge for both facility types were high 
workload, being short staffed or lack of time. Facilities with a person for ADR 
reporting further listed fear of litigation. While, facilities without a person nominated 
for ADR reporting listed additional challenges such as patient’s unwillingness to 
participate in ADR reporting, too administrative, lack of understanding and lack of 
responsibility. These results show that more challenges are seen with facilities 
without a person or committee for ADR reporting. 
Table 4.5 Challenges with ADR reporting in hospitals with and without a nominated person for ADR reporting 
 
Theme Quote 
Too administrative “It is admin intensive” – HOSR5 
“No filling in the forms as supposed” – HOSD2 
Lack of understanding “Failure to understand if a reaction is part of the 
disease process or drug related” - HOSR3 
“Some of the reactions are minor and not 
deemed necessary” – HOSR6 
Patient unwillingness “Patients do not report since most of the 
symptoms resolve spontaneously, they are 
usually not reported” – HOSR3 
“Patients not willing to spend time with 
healthcare workers to fill-in the ADR forms” – 
HOSR4 
2
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Fear of litigation “Fear of being seen as incompetent (blame and 
punishment)” – HOSD3 
Prevalent ADRs not being 
reported 
“Under-reporting” - HOSD3 
 “People do not report” – HOSR5 
“Not willing to report” – HOSR6 
Lack of responsibility “Responsibility” – HOSD4 
Short-staffed, high workload 
and lack of time 
“Short-staffed, overburdened with work and not 
time to fill the form” – HOSD4 
 “Work load” – HOSR1 
  
The facilities were asked if ADR reporting was compulsory or voluntary. According 
to the responses which were given by the study participants, 60% (N=3) 
considered ADR reporting as compulsory in hospitals with a person/committee for 
ADR reporting, while 83.3% (n=5) of the hospitals without a person/committee 
responsible for ADR reporting considered ADR reporting as compulsory. The 
respondents were probed for the reason why they considered ADR reporting to be 
compulsory or not, they stated that only life threatening and serious adverse 
events should be compulsory to report and the common and expected ADR should 
be voluntary. The respondents also indicated that they could not force a 
healthcare worker to report an ADR, the heads of the department should 
emphasize the importance of reporting ADRs in their department and it should be 
their responsibility to evaluate if their staff members comply.   
None of the hospitals specifically remunerated those who were responsible for 
pharmacovigilance or those who sent in reports for ADRs. The remuneration was 
described as any form of reward or benefit for those who were actively involved in 
the ADR reporting process. One of the respondents indicated that ADR reporting 
was part of a healthcare workers daily activity and they could not expect to be 
remunerated for doing what they are expected to do. Furthermore, some of the 
participants felt that ADR reporting should be included in the assessment of 
Performance Management and Development System (PMDS) that aims to assess 
staff quarterly using a set of criteria related to their role.  
Various strategies were employed and suggested by the participants to overcome 
the challenges faced by the hospitals. Hospital HOSD4 stated that ‘the 
responsibility of ADR reporting will be transferred to the store pharmacist’. The 
store pharmacist would be best suited for taking over this function as he or she 
was perceived to be better equipped for this role – their role is administrative in 
nature and they can collate the ADR reporting forms for the hospitals and will be 
able to do the follow-up. They are also in contact with pharmaceutical companies 
and medical supplies depot where they order medicines from, this gives them the 
ability to report and investigate quality issues. 
Improving awareness on the importance of ADR reporting in the hospitals – by 
placing posters on the walls and emphasizing the importance of 
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pharmacovigilance during pharmacy week as reported by HOSD5. Using the 
electronic reporting application which is available from the Department of Health 
EML application. This makes it convenient for the reporter and eliminates the 
extensive paper work, i.e. the need for a scanning and/or faxing the ADR report 
forms as reported by HOSR4. 
Conducting medication errors and ADR training, with follow-up training at regular 
intervals as stated by HSD3 that medication errors training was conducted for 
nurses and other clinical staff, with a follow-up training. Increasing accessibility of 
the ADR reporting forms to all health care practitioners, Hospital HOSR5 
pharmacy staff goes to the wards to place forms and collection boxes on a regular 
basis. The heads of each department have been prompted to report any ADR 
which take place in their departments as reported by hospitals HOSD2, HOSR6 
and HOSD5. 
One strategy that seemed to work extremely well in HOSR2 was through alerting 
the pharmacists when a suspected ADR was identified by ward staff the 
pharmacist would then do the administrative work of completing the ADR form. 
This hospital HOSR2 had by far the highest number of reported ADRs (199) 
reported between September 2017 and October 2018.  
 
4.4.6 Committees which support pharmacovigilance within the hospital 
 
There was only one hospital (9.1%) which had a subcommittee specifically for 
pharmacovigilance, while 90.9% did not have subcommittees for 
pharmacovigilance and this function was part of the hospital’s PTC. The only other 
facility which had a subcommittee was hospital HOSD2, which had a 
subcommittee for antimicrobial stewardship, and not for pharmacovigilance. The 
hospitals were asked to produce the agenda for the last three PTC meetings and 
40% (n=2) of the hospitals which had a person or committee responsible for ADR 
reporting were able to produce this agenda while it was 33.3% (n=2) at hospitals 
without a person or committee responsible for ADR reporting. Other facilities did 
not provide the agenda because it could not be located (n=6) or the agenda 
contained confidential information (n=1), which could not be shared with 
researcher.
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5. CHAPTER 5: DISCUSSION 
 
The aim of this study was to explore the factors affecting ADR reporting at regional 
and district hospitals in Gauteng Province. This study represented just over half 
(55%) of the regional (6/9) and district (5/11) hospitals across the five districts of 
Gauteng Province. A factor that was given specific prominence was if the hospital 
had nominated a person responsible for ADR reporting.  
 
5.1 Hospitals that had a person(s) or committee nominated for ADR 
reporting 
  
This study found that less than half (45.5%) of the participating hospitals had a 
person nominated for ADR reporting. In all cases this person was a pharmacist. 
These results coincide with a study conducted in non-university hospitals in 
France, where directors and presidents of the hospitals were asked to nominate a 
person for pharmacovigilance and the study reported that 83% of the nominated 
persons for pharmacovigilance were pharmacists, 13.5% were doctors while less 
than 3% were nurses and hospital directors (Gony, et al., 2010). Pharmacist are 
seen as the custodians of medicine and it is their responsibility to promote and 
encourage ADR reporting and improve the safety of medicine hence the person or 
committee to be nominated for ADR reporting should be prepared to play this role. 
In addition, countries such as the United States, Canada and the United Kingdom 
have appointed hospital pharmacists to be solely responsible for ADRs reporting 
(Suleman, 2010). 
The five pharmacists nominated for ADR reporting in this study rated their 
knowledge on ADR reporting and confidence to identify an ADR ranging from 
average to excellent. Similarly, a pilot study on the evaluation of knowledge, 
attitude and practices of Indian pharmacists revealed that 95% of the respondents 
were indeed knowledgeable about ADRs, even though these participants were not 
necessarily nominated for ADR reporting at their facilities (Ahmad et al., 2013). 
The positive self-reported knowledge and confidence ratings from the pharmacists 
of this study, also agrees with research which reported that pharmacists in South 
Africa are familiar with the concept of pharmacovigilance, conceding that they 
were not nominated for ADR reporting and are willing to participate in the process 
of ADR reporting, however they are uncertain of the role they should be playing 
(Joubert and Naidoo, 2016). Due to pharmacists’ extensive knowledge on 
medicine, they have a central role in coordinating medicine safety and contribute 
to the identification, prevention, reporting and documentation of ADRs (Suleman, 
2010). This information illustrates that pharmacists have the knowledge and ability 
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to drive ADR reporting in hospitals, and hence should be the nominated person(s) 
to ADR reporting. 
Four of the five (80%) pharmacists nominated for ADR reporting in this study had 
received pharmacovigilance training that they described as adequate. Another 
South African study from one regional hospital found that 89% of healthcare 
personnel were interested in receiving pharmacovigilance training that included 
ADR reporting (Terblanche, 2018), because they believed that training improved 
awareness of ADR reporting. Indeed, the positive effect of training has been 
shown to improve ADR reporting frequency in physicians in part due to the fact 
that they were more confident that they have correctly identified an ADR (Figueiras 
et al., 2006; Lopez-Gonzalez et al., 2014). This improvement in ADR reporting was 
further proved in a systemic review study which evaluated the effect of multiple 
interventions to improve ADR reporting, these interventions included training, 
visual aids on ADR reporting, use of electronic gadgets, continuous feedback on 
reported ADRs, pharmacists and other key personnel involvement, where there 
was a greater than fivefold increase in spontaneous reporting of ADRs (Gonzalez-
Gonzalez, et al., 2013).   
The frequency of ADR reporting for the study participants over the past 12 months, 
ranged between 0 and 10 for five of the participants and 199 for one participant. 
This information was obtained by going through the files which were provided, 
where all the ADR forms were kept by the hospitals. The ADR forms in the files 
were either filled-in by the physicians, nurses or the pharmacist. However, they 
were kept at the pharmacy, irrespective of which healthcare worker reported the 
ADR. No deaths were attributed to ADRs in the district hospitals while one and ten 
ADR-related deaths were reported by the regional hospital participants, 
respectively. These results show a significant variation in the number of ADRs 
reported between participants, as seen with the high variation range.  The higher 
frequency of reporting for especially the regional hospital participants correlates 
more with a study conducted in one regional and three tertiary hospitals in South 
Africa which revealed that 2.9% of medical admissions were attributed to ADRs, 
while a massive 16% were ADR-related (Mouton et al., 2015). The number of 
deaths due to ADRs was relatively low in our study and this may be because 
patients are usually not followed-up as mentioned by one of the hospitals. Yet, a 
study that followed approaches to pharmacovigilance in Europe and the United 
Stated by Wiktorowicz et al., (2012) reported that more than 100 000 deaths per 
annum in the United States were due to ADRs and that they were amongst the top 
10 leading cause of death.   
 
Two (40%) of the five hospitals with a nominated person for ADR reporting 
indicated that they received some form of feedback from the institutional 
pharmacovigilance or antimicrobial stewardship (AMS) subcommittees, which 
were subcommittees, which report to the facility’s PTC. Feedback and evaluation 
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of the decisions taken enhances PTC accountability and ensures the credibility of 
decisions taken (Mashaba et al., 2018). Both the pharmacovigilance and 
antimicrobial stewardship (AMS) subcommittees met monthly. The frequency of 
committee and subcommittee meetings in our study relates to the study conducted 
by Matlala et al. (2018), where almost 40% of the nine Gauteng district hospitals 
and over 70% of the six regional hospitals had PTC meetings monthly 
respectively. The average number of PTC meetings ranged between four and 12 
annually (Mashaba et al., 2018).  
This study also found that more than half of the participating institutions did not 
receive feedback on the reported ADRs. Those who did receive feedback, did not 
receive it frequently enough as the committees meet only once a month, while 
decisions on patient ADR reports may require swift evaluation. Literature reiterates 
that frequently scheduled PTC meetings are necessary as they facilitate decision 
making regarding pharmacovigilance relating to the handling and reporting of 
ADRs, medication errors and management of product complaints (Mashaba, et al., 
2018). However, decision making requires a quorum at PTC meetings and 
Mashaba et al. (2018) also found that only 37.5% of the hospital meetings in their 
study met quorum, thus relevant decisions which feeds back to the healthcare 
workers were absent for about three quarters of meetings that did take place. 
Similarly, a survey conducted by Mehta, et al., (2014) reported that poor 
communication and feedback were identified as major weaknesses to existing 
pharmacovigilance systems. Other literature stated that providing feedback is 
important as it improves the morale of the healthcare staff (Granas, et al., 2007; 
Joubert and Naidoo, 2016). A study conducted in the Netherlands to examine the 
expectations of healthcare professionals regarding feedback on ADR reporting 
found that 80.3% of respondents thought feedback increased their knowledge 
(Oosterhuis et al., 2012). Feedback and communication amongst all stake holders 
involved in the pharmacovigilance process should be prioritised as reported in a 
survey of current pharmacovigilance activities in South Africa, conducted the 
National Department of Health, in collaboration with the University of Cape Town, 
which also reported that   it would be of benefit to establish a national 
pharmacovigilance website which will be a platform used to facilitate information 
sharing (Mehta, et al., 2014). 
The Medicines Information Centre (MIC), situated within the Division of Clinical 
Pharmacology, Department of Medicine, Faculty of Health Sciences in the 
University of Cape Town, is the only clinically based medicines information centre 
in South Africa (SA) and provides information to both public and private sector 
healthcare professionals. The MIC has established a toll-free hotline which 
provides healthcare personnel on all aspects concerning the treatment of HIV and 
TB (Swart et al., 2013). A similar hotline may be established for the purpose of 
pharmacovigilance to provide reliable real time advice, individual and collective 
feedback and communication on ADR reports (Mehta et al., 2017). At a provincial 
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level, the Gauteng provincial pharmacy and therapeutics committee has initiated a 
subsidiary Safety and Quality committee with an objective to manage activities 
relating to ADR reporting, medication errors and quality problems. The Gauteng 
provincial pharmacy and therapeutics committee has published the first 
pharmacovigilance bulletin in 2017 which promotes communication on 
pharmacovigilance activities (Terblanche, 2018). 
 
5.2 Hospitals that did not have a person(s) or committee nominated for 
ADR reporting 
 
There were six hospitals that did not have a person(s) or committee nominated for 
ADR reporting. The most common reason why these facilities did not have a 
nominated person or committee for pharmacovigilance was lack of volunteers for 
this role. None of the hospitals had attempted to nominate a person or committee 
for ADR reporting in the past, because the rate of ADR reporting was low, the 
hospitals were under resourced and they were waiting for a directive from national 
to instruct them to nominate such a person. Another South African study 
conducted in a public hospital in the North West Province, did not investigate 
nominated persons, yet similarly found that resource shortages were reasons 
assigned to challenges of the pharmcovigilance system at the hospital (Goosen et 
al., 2015). Lack of time and resources were also given as reasons by 63.3% of 
participants on not having a person responsible for ADR reporting in a study done 
in a regional hospital in Ghana (Amedome and Dadson, 2017). The problem with 
not having a person nominated for ADR reporting is that this causes an 
overlapping of responsibility and this has led to the assumption that another 
healthcare personnel will report the suspected ADR (Walji et al,. 2011). This 
means that none of the healthcare personnel feels obliged to report an ADR and 
they cannot delegate someone to do so since there is no one who is responsible 
for this function. 
Different hospitals followed different processes for reporting ADRs, depending on 
the resources they had available. Upon analysis, the processes described had 
similarities, even though the order might be different. ADRs were identified, the 
ADR reporting forms were completed by the healthcare personnel who 
encountered the ADR and the forms were submitted to the pharmacy manager. 
The pharmacy manager ensured that the ADRs were reported to the facility PTC 
and in some cases the provincial PTC. Depending on the hospital resources which 
were available, some hospitals did not send their reports to the provincial PTC as 
they were able to make resolutions within the facility’s PTC. The pharmacy 
manager also sent these forms to SAHPRA for review of the reported ADRs. It is 
important for the hospitals to have clear and proper processes to follow when 
reporting ADRs because pharmacovigilance programmes around the world relies 
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on spontaneous reporting of ADRs and hospitals are able to provide this data (Pal 
et al., 2013). Hospitals may have different processes when reporting ADR’s and 
this depends on the resources they have available. Based on the efficiency of the 
process and the support within the facility, it may be acceptable to have different 
processes, provided that ADRs are ultimately being reported on a continuous 
basis. Only a small number of African countries, including South Africa, 
Mozambique, Uganda, Morocco, Tanzania, Zimbabwe, Egypt, Ghana, Togo, 
Nigeria and Tunisia have formal pharmacovigilance systems in place and are full 
members of the WHO Programme for international Drug Monitoring, however, this 
does not mean that the processes of reporting should be similar since there are 
various other factors which influence how the facilities report ADRs (Sevene et al., 
2008). Based on this literature, it is apparent that pharmacovigilance is not a “one 
size fits all” process where all facilities can adopt one process. The reporting of 
ADRs should be tailored for each facility and hence a need for a designated 
person or committee to drive this process and pharmacists are in the best position 
to do so. This statement is supported by Suleman, 2010, who stated that 
pharmacists are best fit for this role due to their ease of access to patient medical 
records, being experts on medicine and ensuring safe use of medicine.  
5.3 Status of ADR reporting at all participating hospitals 
 
All the hospitals (n=5) with a person/committee responsible for ADR reporting 
reported that they used the national ADR reporting forms, while five (80%) of the 
six hospitals without a person or committee responsible for ADR reporting were 
using the national ADR reporting forms. The only hospital that did not use the 
national ADR form rather used a nurses’ incident report to record and report 
ADRs. The reason why they were not using the national ADR reporting form was 
because the incidence report form was more comprehensive and less restricting; it 
also covered other non-treatment related aspects that were related to patient care. 
This hospital decided not to have too many forms and rather used one form which 
had enough space for the reporter to narrate the report/incident. However, not 
using the national ADR form may be problematic, because it has been noted in 
literature that different reporting forms may lead to different reporting styles and 
loss of important information (Bandekar, et al., 2010). The Department of Health of 
South Africa has used the WHO standards to develop the current national ADR 
reporting forms, to facilitate identification and evaluation of drug reactions which 
promotes safe use of medicines, improves patient and public health (nDoH, 1996). 
All the hospitals reported that they kept the ADR reporting forms either at the 
pharmacy or in the wards or consulting rooms. In addition, all healthcare 
professionals had access to the forms, except for Hospital HOSR3, where only 
nurses had access. Literature recommends that sufficient resources should be 
made available to facilitate and encourage reporting. Goosen, et al., (2010) has 
stated that adequate ADR reporting forms and a telephone line should be provided 
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to improve the system. All hospitals that used the national ADR form were able to 
produce at least three previously completed ADR forms, which were also the latest 
version (version 4.0 07/16) of this form.  
 
According to this study, only two (18.2%) of the 11 hospitals used algorithms 
and/or trigger tools to identify ADRs, one of these had a person/committee 
responsible for ADR reporting and the other one did not. The hospital which 
reported using an information poster (HOSR2) had a person responsible for ADR 
reporting. The information posters which were displayed on the corridor walls of 
the hospital, in the wards, patient waiting areas and at the pharmacy contained 
information on what an ADR was and how to recognise an ADR, as well as the 
contact details of the person responsible for ADR reporting. This hospital had by 
far the highest reported number of ADRs (n=199), followed by hospital HOSR3 
which had a total of 10 reported ADRs (and used the SAE algorithm) over the past 
12 months, making it the second highest. The positive effect of algorithms and 
trigger tools on ADR identification has been demonstrated in a study conducted in 
India where the reported ADRs were 18.1% over the study period where a trigger 
tool was being used, compared to other studies where a trigger tool was not being 
used and the reported ADRs were 5.42%, 9.8% and 3.31% (Ganachari et al., 
2013).  
Pharmacists possess the skills and ability to drive ADR reporting in hospitals and 
one of the ways in which they can enhance this activity is by using algorithms and 
trigger tools, which may use suspect drugs to identify a possible ADR, suspect 
drugs are drugs which are commonly used as antidotes, to prevent or reverse the 
harmful effects of drugs received by the patient. Cavell, 2009 has defined trigger 
drugs as medicines which are administered to prevent harm of an adverse drug 
event. These medicines include antidotes such as activated charcoal, vitamin K, 
naloxone, acetylcysteine, flumazenil, glucagon, calcium gluconate, etc. When the 
pharmacy staff issue these drugs, they should follow-up with the prescriber to 
determine if the patient has experienced an ADR or not. 
 
This study reports the ADR reporting frequency at the unit of analysis at the level 
of the facility. The most frequently reported ADR type across facilities was 
hypersensitivity reactions, reported at eight facilities, which presented as 
angioedema and rash. Two of these facilities had a nominated person for ADR 
reporting. These hypersensitivity reactions are classified as type B reactions, 
which are bizarre or idiosyncratic in nature, they cannot be predicted from known 
pharmacology of the medicine and the reactions are usually outward, which 
means that they can be easily identified by the patient and/or the healthcare 
worker (Kaufman, 2016). This means that healthcare workers are easily alerted of 
the possibility of an ADR where a type B ADR is involved, hence the high number 
of this type of ADR being reported (Kaufman, 2016).  
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Other frequently reported ADR type at facilities without a nominated person or 
committee included quality issues (n=3) and administration errors (n=2). Quality 
issues is important to report on ADR forms, because most facilities only report 
qualities issue to their suppliers where they send the default products back to the 
supplier for an exchange. This deviation in product quality needs to be addressed 
as faulty pharmaceuticals which are released into the market may result in health 
problems and it is extremely important as it poses a risk in patient safety (Visacri, 
et al., 2014). This type of ADR is relatively easy to evaluate, with common 
examples including absence of a label, presence of foreign bodies or colour 
changes (Visacri, et al., 2014).  
Administration errors are also as important when it comes to ADR reporting, 
nurses are usually involved in the administration of medicine and in some cases, 
they are involved in the dispensing and preparation of medicine, having a similar 
role to that of a pharmacist and hence it will be of benefit for the person 
responsible for ADR reporting to work closely with nurses and assist in identifying 
and reporting such cases (Armitage and Knapman, 2003). 
It is difficult to compare the results from this study to studies on the prevalence of 
ADRs in an area or facility, because the units of analysis differ. In prevalence 
studies the unit of analysis is the individual patients treated at the facility, whereas 
in this study the unit of analysis was the facility itself. A study conducted in 
Malaysia, which evaluated the number of spontaneous ADR reports received by 
the Malaysian ADR advisory committee somewhat coincides with the results of our 
study as they have reported that skin and appendages are the most common 
ADRs  (Lei, et al., 2007). A similar study conducted in Nepal which looked at the 
number of reported ADRs reported that weight gain was the most common ADR, 
followed by CNS related ADRs (paraesthesia, tremor, fever, insomnia, agitation, 
confusion, dizziness, irritability, peripheral neuropathy and delirium), fatigue, 
gastrointestinal related and rash, gynaecomastia and cough once again did not 
feature as the studies frequently reported ADRs for patients admitted in the 
hospital (Rauniar and Panday, 2017).  
 
In the African continent, a study which looked at the number of ADRs reported to 
the global VigiBase database from 1992 to 2015 showed that 31.14% of the ADRs 
were reports of skin and subcutaneous tissue, followed by administration errors 
20.91%, CNS disorder with 17.48% and gastrointestinal disorder with 16.10% 
(Ampadu et al., 2016). These results both infer that skin reactions (rash and 
angioedema) were the leading ADRs followed by administration errors. This study 
furthermore showed that antiretroviral drugs were most commonly involved in 
ADRs (28.63%), followed by antibiotics (5.24%), and ACE inhibitors (2.42%) 
(Ampadu, et al., 2016). Although this was a bigger study which evaluated 35 
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African countries, the results were somewhat showing a trend with antiretrovirals 
and ACE inhibitors found in this study. 
 
5.4 Challenges with ADR reporting in the facilities 
 
The most common challenge identified in this study was that ADRs were not being 
reported. The second most common challenge was the high workload, being short 
staffed or lack of time. Facilities with a person for ADR reporting (n=2) further 
listed fear of litigation. While, facilities without a person nominated for ADR 
reporting listed additional challenges such as patient’s unwillingness to participate 
in ADR reporting, too administrative, lack of understanding by healthcare workers 
and lack of responsibility from pharmacy staff and other healthcare workers in the 
hospital. A similar study conducted in a Gauteng regional hospital, looked at 
common challenges with ADR reporting and it reported that 37.1% of the 
responded stated that there was lack of time to identify and report these reactions, 
while 34.1% feared that they might be wrong (Terblanche et al., 2018). While 
according to a study conducted in France in non-university hospitals, the four main 
challenges with ADR reporting included lack of understanding to report ADRs 
which are already included in the product package insert, uncertainty of the link 
between the drug product and the reaction, lack of time and fear of being called 
upon, all of which were reported in our study (Gony, et al., 2010).  
Most participants (72.7%) considered ADR reporting as compulsory for healthcare 
personnel. These results coincide with that of a study done in one of the Gauteng 
province regional hospitals, which reported that 82.6% of healthcare personnel 
considered ADR reporting compulsory (Terblanche et al., 2018) and another 
Ethiopian study that found that 57.9% (n=77) of the respondents also stated that 
ADR reporting should be compulsory (Gurmesa and Dedefo, 2016). In this study, 
when the respondents were probed for the reason why they considered ADR 
reporting to be compulsory or not, they stated that only life threatening and serious 
adverse events should be compulsory to report and the common and expected 
ADRs should be voluntary. These responses tally with a study conducted in 
Ethiopia, where 58 of the respondents (43.6%) stated that ADR reporting was 
encouraged when the reaction was serious (Gurmesa and Dedefo, 2016). The 
respondents of this study further recommended that the pharmacy or nominated 
person could not force a healthcare worker to report an ADR, instead the line 
manager or head of the department should emphasize the importance of reporting 
ADRs in their department and it should be their responsibility to evaluate if their 
staff members comply.   
None of the hospitals specifically remunerated those who were responsible for 
pharmacovigilance or those who sent in reports for ADRs. One of the respondents 
indicated that ADR reporting was part of a healthcare workers daily activity and 
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they could not expect to be remunerated for doing what they were expected to do. 
This statement was supported by a study done at Sebokeng Hospital where only 
8.3% of the healthcare workers felt that ADR reporting should be remunerated 
(Terblanche et al., 2018). Furthermore, some of the study participants from this 
study felt that ADR reporting should be included in the assessment of 
Performance Management and Development System (PMDS) that aims to assess 
staff quarterly using a set of criteria related to their role. In a Malaysian study that 
explored barriers and facilitators for ADR reporting among community 
pharmacists, it was reported that providing financial incentives can be beneficial in 
increasing the number of ADRs reported, the downside to that is that healthcare 
personnel will be doing this for financial gain and the quality of the reported ADRs 
may be of little benefit to medication safety, while providing little benefit for those 
who report ADRs may result in demotivation for reporting (Elkalmi,et al., 2011). 
 
5.5 Strategies used to overcome the challenges faced by the hospitals 
 
The strategy to nominate the store pharmacist for ADR reporting seems to be a 
novel idea from HOSD4. To the researcher’s knowledge, there is no study which 
has been conducted to evaluate the role of store pharmacists in ADR reporting. 
Due to the fact that the store pharmacist’s role being more administrative in 
nature, collating ADR reporting forms and doing follow-ups might be easier than 
for pharmacists with more direct patient care activities. Store pharmacists are also 
in contact with pharmaceutical companies and medical supplies depot where they 
order medicines from, which gives them routine access to report and investigate 
quality issues. Bushra et al. (2015) agrees that the expertise of a pharmacist on 
drug products gives them an advantage of over other members of the healthcare 
team to influence changes such as getting substandard products withdrawn from 
the market or cause label changes. They can also emphasise the importance, 
seriousness, preventability and necessity to report ADRs through their interactions 
with other healthcare workers (Bushra et al., 2015). 
 
HOSD5 suggested improving awareness on the importance of ADR reporting by 
placing posters on the walls and emphasizing the importance of 
pharmacovigilance during pharmacy week. This strategy aligns with a study 
conducted by Pimpalkhute, et al. (2012) which evaluated the level of awareness 
about pharmacovigilance and ADR monitoring amongst doctors in a tertiary 
hospital and reported that measures such as making ADR reporting guidelines 
available in a form of posters and booklets has proven to be useful in increasing 
awareness and status of ADR reporting. Another way that pharmacists promoted 
ADR reporting in this study was to request healthcare personnel to call them to the 
ward if an ADR was suspected. The responding pharmacist would then do the 
administrative work of completing the ADR forms. This is the strategy used by 
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Hospital HOSR2 and their ADR reports was the highest at 199 reported between 
September 2017 and October 2018.  
 
Conducting medication errors and ADR training, with follow-up training at regular 
intervals as well as increasing accessibility of the ADR reporting forms to all health 
care practitioners was also suggested in this study as ways to overcome the 
challenges of ADR reporting. Terblanche (2018) concurs with these initiatives in a 
research conducted in one of Gauteng province regional hospitals, where 
strategies such as training programmes, improved feedback, increased availability 
of ADR reporting forms and having a pharmacist available in the wards were some 
of the initiatives proposed to improve ADR reporting (Terblanche, 2018).  
 
Another suggestion from participants were to encourage the use of the electronic 
reporting application which is available from the Department of Health EML mobile 
application. This makes it convenient for the reporter and eliminates the extensive 
paper work, i.e. the need for a scanning and/or faxing the ADR report forms. This 
is supported by a study conducted by Ribeiro-Vaz, et al. (2016) who described and 
evaluated the use of information systems to promote ADR reporting in 15 
countries globally and reported that the increasing trend of web-based software 
has positively improved ADR reporting numbers by more than two-fold. The above 
strategies to facilitate ADR reporting require collaboration amongst all those 
involved and these strategies may be combined with inclusion of electronic 
reporting aids, in addition to the Department of Health EML application, which is 
only available on a mobile phone and not on a computer, conducting continuous 
training as healthcare personnel who receive training are more likely to report 
ADRs with better understanding of the pharmacovigilance system (Walji et al., 
2011).  
 
 
5.6 Committees which support pharmacovigilance within the hospital 
 
All the facilities had functioning Pharmacy and Therapeutics Committees (PTC). 
This study also looked at the subcommittees which support ADR reporting and 
report to the PTC of which only one hospital (9.1%) which had a subcommittee 
specifically for pharmacovigilance. For the rest of the hospitals the 
pharmacovigilance function was part of the PTC. The only other facility which had 
a subcommittee partially related to pharmacovigilance was hospital HOSD2, which 
had a subcommittee for antimicrobial stewardship. Two of the hospitals which had 
a person or committee responsible for ADR reporting and another two hospitals 
that did not have a nominated person or committee were able to produce their last 
three PTC meeting agendas. Other facilities did not provide the agenda because it 
could not be located (n=6) or the agenda contained confidential information (n=1), 
which could not be shared with researcher. It is important for hospitals to have a 
https://etd.uwc.ac.za
Chapter 5: Discussion 
 
45 
 
committee or a subcommittee which supports ADR reporting and provide feedback 
to the reporters in order to improve their confidence in reporting, communicate the 
findings and improve medicine safety in the facility (Schatz and Webber, 2015). 
Hospital HOSD3, which had a subcommittee stated that their PTC agenda was too 
broad and time consuming, hence their attendance was low because some PTC 
members only wanted to attend the meeting for specific agenda points which were 
applicable to them and hence there was a necessity for subcommittees which 
feedback to the main PTC committee. This was in contrast with Hospital HOSR6, 
which stated that the facility did not want to have too many committees, ADRs 
were an agenda point of the PTC, and therefore there was no perceived need for a 
separate committee. Matlala, et al. (2017) carried out a study to determine the 
percentages of tertiary, regional and district PTCs in the Gauteng province which 
had any subcommittees within the PTC and 25% (n=5) of the PTCs had an ADR 
subcommittee (Matlala, et al., 2017). It is acknowledged that the results of this 
study are not directly relatable to our findings, however,  they concur with our 
study that majority of the hospital PTCs do not have a pharmacovigilance/ADR 
reporting subcommittee. 
 
5.7 Availability of person or committee for ADR reporting 
 
One of the objectives of this study was to determine which facilities had a person 
or committee nominated for ADR reporting. Countries such as Iran have 
introduced a guideline where each hospital has to nominate a person responsible 
for pharmacovigilance, the designated person may be a nurse, doctor or 
pharmacist and they are referred to as drug safety officer (DSO). Over 600 
hospitals selected their DSO who underwent training and became a full member of 
WHO International Drug Monitoring Program and the number of reported ADRs 
increased to more than 35 000 country wide (Mirbaha et al., 2015). These results 
could be loosely extrapolated to one of the participating hospitals (HOSR2) where 
there was a person nominated for ADR reporting and the rates of reporting were 
higher than those which did not have a person nominated for ADR reporting. 
However, this study cannot conclude if a nominated person really made a 
difference in increasing ADR reporting.  
https://etd.uwc.ac.za
Chapter 5: Discussion 
 
46 
 
5.8 Limitations of the study 
 
This study represented just over half (55%) of the regional (6/9) and district (5/11) 
hospitals across the five districts of Gauteng Province. Therefore, these results 
may not be reflective of the rest of South Africa, which is acceptable for an 
explorative study design. Furthermore, the small sample size and narrow focus 
(i.e. focus on nominated persons) restricted the comparability of these data to 
other studies which focus on ADR reporting in general. This could be attributed in 
part to limited time and money to perform the research.  
The study was more focused on the processes and challenges with ADR reporting 
and not on the types of ADRs which were reported. The researcher did not 
observe the ADRs in the hospitals and relied heavily on the ADR forms which 
were available to extrapolate the types of ADRs reported by the hospital. 
Therefore, these types of ADRs may not be a true reflection of the actual ADRs 
which occur in these facilities. 
 
Due to recommendation by the CEOs of the hospital not all personnel involved in 
ADR reporting was interviewed at facilities without a nominated person for ADR 
reporting. This might affect the accuracy of reporting in these facilities as the 
pharmacy manager might not have had the whole context of ADR reporting. 
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6. CHAPTER 6: CONCLUSION AND RECOMMENDATIONS 
 
6.1 Conclusion 
 
The research study aimed to explore the factors that affect ADR reporting in 
regional and district public hospitals in the Gauteng province and specifically 
focused on structures that support ADR reporting such as persons or committees 
nominated for ADR reporting. In general, pharmacists and the pharmacy were 
synonymous with ADR reporting as all nominated persons were pharmacists and 
in facilities were there were no nominated person, the responsible pharmacist was 
identified as the contact person for ADR reporting. Although all hospitals had 
PTCs, there was rarely a subcommittee dedicated to pharmacovigilance or ADR 
reporting, which culminated in a lack of feedback to healthcare workers that could 
promote it in the facility. Lack of feedback and communication on reported ADRs is 
a weakness in pharmacovigilance systems and may hinder the sustainability of 
ADR reporting, because feedback has been shown to increase confidence in 
identifying ADRs and motivation and purpose for ADR reporting.  
Together with this seemingly lack of supportive structure to support ADR reporting 
and the pharmacy in particular, the primary challenge to ADR reporting at 
participating facilities was that ADRs were not being reported, which were 
reflected in the mostly (with the exception of one facility) very low number of 
reported ADRs over the last 12 months at facilities with a nominated person and 
perception from some facilities that ADRs was not a concern. In addition, there 
were very few tools available to promote the identification and subsequent 
reporting of ADRs at participating facilities.  
These findings show a lack of structure and leadership support for adequate ADR 
reporting at regional and district public hospitals in Gauteng Province. However, 
we only interrogated the views of one person at each hospital and while it might 
reflect the views from mainly the pharmacy, it does not capture the views of 
prescribers and personnel outside the pharmacy. 
This is the first study in the country to evaluate the availability of a nominated 
person or committee for ADR reporting in public hospitals and while this has been 
shown to boost ADR reporting in other countries, it remains to be seen if it will 
have an effect in South Africa. 
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6.2 Recommendations 
 
Recommendations for practice include: 
• Hospitals should take the initiative to nominate a person or a committee. 
This will assist healthcare workers with reporting as they will have a reliable 
‘go-to’ person whenever they feel there is a suspected ADR or are not sure 
and this uncertainty leads to ADRs not being reported. 
• The hospitals which have ADR reporting in their PTC agenda should make 
sure that they provide feedback on ADRs which have been reported in the 
hospital to raise awareness and share their findings to improve patient 
safety. Should the PTC agenda be too long, it may be necessary to form a 
subcommittee specifically for pharmacovigilance as seen with one of the 
facilities in this study. 
• Hospitals should make use of algorithms and trigger tools which aid in the 
identification of possible ADRs. This can be as simple as pharmacy 
following-up on the antidotes or trigger drugs such as naloxone, 
acetylcysteine, flumazenil etc. as this will trigger the healthcare personnel to 
investigate and where necessary report if there was an ADR. 
• Adverse Drug Reactions reporting should be part of the performance 
management and development system (PMDS). None of the hospitals 
remunerate ADR reporting, the reason being that ADR reporting is a 
professional obligation, healthcare professionals (HCP) are expected to 
report ADRs they encounter and this should reflect on their PMDS 
assessment since some of the healthcare personnel expect some form of 
remuneration as motivation. 
• Adverse Drug Reactions reporting should be made as easy and convenient 
as possible, though the accessibility of ADR reporting forms was not 
identified as a barrier to reporting in any of our facilities, it is important to 
ensure that it remains that way and improve accessibility by exploring the 
option of web-based reporting (in addition to the mobile Department of 
Health - EML application which is already available). 
• Training in a form of workshops, webinars, conferences and seminars will 
help improve knowledge and skills in ADR reporting and improve health 
care personnel confidence in identifying and reporting ADRs. 
• The study can be further explored to implement the recommendations 
suggested in this study and evaluate their impact on ADR reporting.
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APPENDIX 2: Letter of Intent 
 
 
 
 
Mr TumeloModau Tel: 073 444 1250 
Dr Mea van Huyssteen      Tel: 0219592864 
School of Pharmacy, University of the 
Western Cape, Robert Sobukwe Road, 
Bellville, Cape Town, 7535 
Gauteng Department of Health  
Chief Executive Officer 
Dear Sir/Madam 
RE: Permission to conduct a study at Gauteng regional and district public 
hospitals 
I am a part-time post-graduate student at the University of the Western Cape. As part of 
the requirements for my masters’ degree qualification, I have to conduct a research 
project. The title of my study is “the availability of persons nominated for adverse drug 
reporting and associated challenges in Gauteng regional and district public hospitals." 
I therefore kindly request your permission to conduct the study in the above mentioned 
facility. 
The study will commence once ethical approval has been granted by the University of 
the Western Cape Biomedical Research and Ethics Committee. Attached please find a 
copy of the protocol for your information. 
I trust that you will find the above in order. Please feel free to contact me or my 
supervisors, should you require any additional information. 
Sincerely, 
______________________  
Mr Tumelo M Modau   (Student) 
Tel: 073 444 1250, Email:t4modau@gmail.com 
 
_____________________________ _____________________________ 
Dr M. Van Huyssteen (Supervisor) Mr R. Bapoo (Co-Supervisor) 
Email: mvanhuyssteen@uwc.ac.za Email: rbapoo@uwc.ac.za 
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APPENDIX 3: STUDY INFORMATION SHEET 
 
 
 
 
Mr TumeloModau Tel: 073 444 1250 
 
Dr Mea van Huyssteen      Tel: 0219592864 
School of Pharmacy, University of the 
Western Cape, Robert Sobukwe Road, 
Bellville, Cape Town, 7535 
 
 
Study title: THE AVAILABILITY OF PERSONS NOMINATED FOR ADVERSE DRUG 
REPORTING AND ASSOCIATED CHALLENGES IN GAUTENG REGIONAL AND 
DISTRICT PUBLIC HOSPITALS 
 
Study information sheet 
To: Interviewee (Participant) 
You are being invited to take part in a research study conducted by Mr TumeloModau, a 
masters’ student from the School of Pharmacy at the University of the Western Cape. 
As part of my master’s degree in pharmacy administration and regulation, I have to 
conduct a research study and submit a mini-dissertation to fulfil the requirements of the 
degree. The study that I am conducting is titled:  The availability of persons nominated 
for adverse drug reporting and associated challenges in Gauteng regional and district 
public hospitals.  
Before you decide whether you wish to take part in this study, you should read the 
provided information sheet carefully. You are not obliged to take part in this study and 
failure to participate will have no effect on you. You may change your mind at any time 
(before the start of the study or even after you has commenced the study) for whatever 
reason without having to justify your decision and without any negative impact. 
Purpose of the research: 
The purpose of this study is to describe the status of ADR reporting structures, in terms 
of human and other resources, in public hospitals and to identify factors that help or 
hinder the effectiveness of ADR reporting within the existing structures. 
Research procedure: 
You have been identified by the CEO of your hospital as a person involved in ADR 
reporting. As such we would like to ask you to participate in the research study. You 
have been sent this study information sheet and the data collection sheet, in order for 
you to familiarise yourself with questions and facility-based records that we will be 
https://etd.uwc.ac.za
Appendices 
 
62 
 
asked for during the interview. The researcher will make an appointment to administer 
the questionnaire with you that will take about 45 minutes of your time in total to 
complete.  
Confidentiality and anonymity  
All information provided by you during the study will be kept confidential.  No personal 
or identifying information with regard to your facility will be included in the final research, 
with all results presented in a combined form.  On completion of the study, the sample 
data will be kept for a period of two years after which it will be destroyed by paper 
shredding.  
Risks and benefits 
This study anticipates no risks associated with participating in this study. There are no 
anticipated direct benefits to you as a participant. All participants enrolled in the study 
participate on a voluntary basis. 
Voluntary participation 
Participation in this study is the sole decision of the participant and your participation is 
completely voluntary. If you agree to partake in the study, you will need to sign a 
consent form before your information may be collected. You may withdraw from the 
study at any time. Withdrawal from the study will not affect the participant in any way.I 
am very thankful for your willingness to take part in this research project.  
IF YOU REQUIRE FURTHER INFORMATION 
Any further queries or information required may be directed to: 
Mr TumeloModau 
MOBILE: 073 444 1250 
EMAIL: t4modau@gmail.com 
OR 
Dr Mea van Huyssteen 
Pharmacy building, First floor Room F6, School of Pharmacy, University of the Western 
Cape, Robert Sobukwe Road, Bellville, 7535, South Africa. 
Tel:  +2721 9592864 
The committee giving ethical approval for this study is the UWC Biomedical Research 
Ethics Committee. The biomedical research ethics administration is available in the 
Research Office in the New Arts Building, C-Block, Top Floor, Room 28 at the 
University of the Western Cape, Robert Sobukwe Road, Bellville, South Africa. If you 
have any problems or questions about this study you can also contact the BMREC, 
Research Development, Tel: 021 959 4111, email:  research-ethics@uwc.ac.za. 
 
https://etd.uwc.ac.za
Appendices 
 
63 
 
APPENDIX 4: QUESTIONNAIRE 
 
 
 
 
 
Mr TumeloModau Tel: 073 444 1250 
 
Dr Mea van Huyssteen      Tel: 0219592864 
School of Pharmacy, University of the Western 
Cape, Robert Sobukwe Road, Bellville, Cape 
Town, 7535 
 
THE AVAILABILITY OF PERSONS NOMINATED FOR ADVERSE DRUG 
REPORTING AND ASSOCIATED CHALLENGES IN GAUTENG REGIONAL AND 
DISTRICT PUBLIC HOSPITALS 
Name of the facility: Unique Study Code : 
Section A (facilities that has a nominated person or committee for ARD reporting) 
1.  
 
Is there a person or committee nominated for ADRs reporting? (If NO, 
please skip this section and proceed to answer  the “B” and “C” sections 
of the questionnaire) 
YES NO 
2.  Are you the nominated person or on the nominated committee? YES NO 
3.  
 
 
 
3.1 What is your qualification: 
 
Pharmacist  
Pharmacist Assistant/Technician  
Medical Practitioner  
Professional Nurse  
Enrolled Nurse  
Other (Please specify):  
 
 
 
 
 
 
3.2 How would you rate your knowledge of 
ADR   reporting? 
1 = poor; 2 = fair; 3 = average; 4 = good, 5 = excellent 
1 2 3 4 5 
3.3 How confident are you to identify an 
ADR? 
 
1 
 
2 
 
3 
 
4 
 
 
    5 
 
 4.1 Do you have any form of Pharmacovigilance training? YES NO 
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4. 
 
4.2 If ‘Yes’, when was it received?  
………………………………………  
4.3 Who provided this training? 
…………………………………………… 
 
4.4 What was the training about?  
………………………………………………………………………………......................                                               
………………………………………………………………………………………………. 
 
 
 
 
4.5 Was this training adequate?                                                                     
If not, how should it be changed? 
.............................................................................................................................................
............................................................................................................................................. 
4.6 If no training was received, would you like to receive training on ADR 
reporting? 
Why do you say yes/no? What topics should be included? 
................................................................................................................
................................................................................................................
................................................................................................................ 
YES NO 
5. Over the past twelve months, how many ADRs did you identify?  
6. Over the past 12 months, how many of your identified ADRs did you 
report? 
 
7.  How many of these ADRs resulted in death?  
8.  
 
Do you receive or give feedback on ADRs reported to a certain 
committee in the facility? 
YES NO 
9.    If yes, what is the name of this committee and what are its functions? 
……………………………………………………………………………………
……………………………………………………………………………………
……………………………………………………………………………………
…………………………………………………………………………………… 
………………………………………………………………………………….. 
…………………………………………………………………………………. 
 
10.  How often do this committee meet? (Weekly, bi-monthly, monthly, 
quarterly etc.) 
 
Kindly skip section “B” and proceed to section “C” 
YES NO 
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Section B (facilities without a nominated person or committee for ADR reporting) 
1.  
 
 
What is the reason why there is no person or committee nominated for ADR reporting 
………………………………………………………………………………………………………
………………………………………………………………………………………………………
……………………………………………………………………………………………………… 
……………………………………………………………………………………………………… 
2.  
 
 
 
What is the process followed in ADRs reporting in this facility? Please explain 
.............................................................................................................................................
............................................................................................................................................ 
.............................................................................................................................................
............................................................................................................................................ 
............................................................................................................................................. 
3.  
 
Has the hospital attempted to nominate a person or committee for ADR 
reporting in the past? 
If not, what is the reason? 
……………………………………………………………………………………
……………………………………………………………………………………
………………………………………………………………………………….. 
YES NO 
4.  Are there any plans to nominate a person or committee for ADR 
reporting? 
YES NO 
Section C (all facilities) 
1.  
 
Provide a copy of the ADR reporting form you use - If different from the national ADR 
reporting form  
1.1 Where are these forms kept? ………………………………………………………….. 
1.2 Who has access to them? ..................................................................................... 
2.  
 
 
 
2.1    Do you use any algorithms or trigger tools to identify ADRs? 
2.2    If yes, which ones? ...........................................................................  
(Please provide a copy of your algorithm or trigger tool) 
 
YES NO 
 
 
3.  
 
 
 
Which type of adverse drug reaction(s) are reported mostly in the facility? (e.g.: Drug-
induced liver injury, kidney injury, diarrhoea, neutropaenia, angioedema, hypotension, 
hyperkalaemia, etc) 
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Thank you for your time and cooperation 
The committee giving ethical approval for this study is the UWC Biomedical Research 
Ethics Committee. The biomedical research ethics administration is available in the 
Research Office in the New Arts Building, C-Block, Top Floor, Room 28 at the 
University of the Western Cape, Robert Sobukwe Road, Bellville, South Africa. If you 
have any problems or questions about this study you can also contact the BMREC, 
Research Development, Tel: 021 959 4111, email:  research-ethics@uwc.ac.za. 
 
  
4.  Which particular class of drugs or drug is especially problematic in causing ADRs in this 
facility? 
5.  In the facility, ADR reporting is? Please tick the relevant 
box(es) relating to people who are specifically nominated. 
Compulsory  
Voluntary  
Remunerated  
6.  
 
 
 
Please state the challenges experienced with ADR reporting in the facility 
 
7.  Please state strategies used to deal with the above mentioned challenges 
 
8.  If, possible, please provide copies of the last three ADR reports compiled for this facility 
9.  If possible, please provide the agendas and minutes for the last 3 committee meetings 
that discussed ADR reports and reporting for this facility. 
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APPENDIX 5: INFORMED CONSENT FORM 
 
 
 
 
 
Mr TumeloModau Tel: 073 444 1250 
 
Dr Mea van Huyssteen      Tel: 0219592864 
School of Pharmacy, University of the 
Western Cape, Robert Sobukwe Road, 
Bellville, Cape Town, 7535 
 
 
Study title: THE AVAILABILITY OF PERSONS NOMINATED FOR ADVERSE DRUG 
REPORTING AND ASSOCIATED CHALLENGES IN GAUTENG REGIONAL AND 
DISTRICT PUBLIC HOSPITALS 
 
Informed Consent From participant 
• I have read and understood the information given to me by the researcher.  I was 
given the opportunity to ask questions and given adequate time to rethink my 
participation in the study. 
• I understand that participation in this study is voluntary and that I may withdraw 
at any point without providing reasons for my choice. 
• I understand that this study has been approved by the University of Western 
Cape Biomedical Research and Ethics committee. 
• I am fully aware that the results of this study will be used for scientific purposes 
and may be published. I agree to this, provided that my privacy is guaranteed. 
• I hereby give consent to participate in the study. 
 
__________________ _________________ _______/20___  ____________ 
Name of participant Signature Date Place 
 
 
 
___________________ 
 
 
 
_________________ 
 
 
 
_____/20_    _ 
 
 
 
___________  
Witness Signature Date Place 
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Statement by the researcher 
I have provided verbal and/or written information regarding this study.  I agree to answer 
any future questions concerning the study as best as I am able to.  I will adhere to the 
approved protocol. 
 
Tumelo Modau                           _________________ 
Name of researcher     Signature of researcher 
 
The committee giving ethical approval for this study is the UWC Biomedical Research 
Ethics Committee. The biomedical research ethics administration is available in the 
Research Office in the New Arts Building, C-Block, Top Floor, Room 28 at the 
University of the Western Cape, Robert Sobukwe Road, Bellville, South Africa. If you 
have any problems or questions about this study you can also contact the BMREC, 
Research Development, Tel: 021 959 4111, email:  research-ethics@uwc.ac.za. 
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APPENDIX 6: ETHICS TRAINING OF T MODAU 
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APPENDIX 7: ETHICS CLEARANCE CERTIFICATE 
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APPENDIX 8: NHRD ONLINE APPLICATION 
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APPENDIX 9: HOSPITAL HOSR3 ALGORITHM 
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APPENDIX 10: HOSPITAL HOSR2 ADR INFORMATION POSTER 
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